

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Ginkgo Biloba Extract for Prevention of Acute Mountain Sickness: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022005
Article Type:	Research
Date Submitted by the Author:	30-Jan-2018
Complete List of Authors:	Tsai, Tou-Yuan ; Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, Emergency Department WANG, SHIH-HAO; Chang Gung Memorial Hospital at Chiayi, Department of Physical Medicine and Rehabilitation Lee, Yi-Kung; Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, Emergency Department Su, Yung-Cheng; Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, Emergency Department
Keywords:	Ginkgo Biloba Extract, Acute Mountain Sickness, meta-analysis

SCHOLARONE™  
Manuscripts

Peer Review Only

1  
2  
3 **Ginkgo Biloba Extract for Prevention of Acute Mountain Sickness: A Systematic**  
4  
5 **Review and Meta-analysis of Randomized Controlled Trials**  
6

7 Tou-Yuan Tsai, MD<sup>1,2</sup>; Shih-Hao Wang, MD<sup>2-5</sup>; Yi-Kung Lee, MD, MPH<sup>1,2</sup>; and Yung-  
8  
9 Cheng Su, MD, MPH.<sup>1,2</sup>  
10

11  
12 **Institutions:**  
13

14 <sup>1</sup>School of Medicine, Tzu Chi University, Hualien, Taiwan  
15

16 <sup>2</sup>Emergency Department, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical  
17  
18 Foundation, Chiayi, Taiwan  
19

20  
21 <sup>3</sup>Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital  
22  
23 at Chiayi, Chiayi, Taiwan.  
24

25  
26 <sup>4</sup>Department of Recreation and Leisure Industry Management, College of  
27  
28 Management, National Taiwan Sport University, Taoyuan, Taiwan.  
29

30  
31 <sup>5</sup>Taiwan Wilderness Medical Association, New Taipei City, Taiwan.  
32  
33  
34

35 **Reprints and correspondence:**  
36

37 Yung-Cheng Su, MD, MPH.  
38

39 Emergency Department  
40

41 Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation  
42

43  
44 No. 2, Minsheng Rd., Dalin Township  
45

46 Chiayi County 622, Taiwan (R.O.C.)  
47

48  
49 Tel: 886-5-2648000 ext 5838  
50

51 Fax: 886-5-2648499  
52

53 E-mail: [drs119@gmail.com](mailto:drs119@gmail.com)  
54

55 **Running title:** Ginkgo Biloba Extract for Acute Mountain Sickness  
56  
57  
58  
59  
60

**Word count:**

Abstract: 183 words

Full text: 2148 words

**Number of references: 33****Number of tables: 4****Number of figures: 8****Author Disclosures:**

Dr. Tou-Yuan Tsai reports no disclosures.

Dr. Shih-Hao Wang reports no disclosures.

Dr. Yi-Kung Lee reports no disclosures.

Dr. Yung-Cheng Su reports no disclosures.

**Email address:**

Dr. Tou-Yuan Tsai: 96311123@gms.tcu.edu.tw

Dr. Shih-Hao Wang: mountainwangsh@gmail.com

Dr. Yi-Kung Lee: lyg1968@seed.net.tw

Dr. Yung-Cheng Su: [drs119@gmail.com](mailto:drs119@gmail.com)

**Contributorship statement:**

TYT analyzed and interpreted the data and was a major contributor in writing the manuscript. SHW interpreted the data. YKL supervised the study and interpreted the data. YCS interpreted the data and wrote the manuscript. All authors read and approved the final manuscript.

**Funding**

The authors did not receive any funding for this study.

**Availability of data and materials**

1  
2  
3 The datasets used and analysed during the current study are available from the  
4  
5 corresponding author on reasonable request.  
6

#### 7 **Strengths and limitations of this study**

- 8  
9 • This is the first meta-analysis evaluating Ginkgo Biloba Extract (GBE) as an  
10  
11 Acute Mountain Sickness (AMS) prophylactic.  
12
- 13  
14 • In pooled analyses, although GBE may tend toward AMS prophylaxis, it had  
15  
16 no statistically significant prophylactic effect (RR =0.86; 95% CI: 0.45 to 1.04;  
17  
18 p-value=0.07). The results of several subgroup analyses were similar.  
19
- 20  
21 • Only a total of 487 participants were enrolled in selected studies. Insufficient  
22  
23 power may be an issue even in this meta-analysis.  
24  
25  
26  
27

28 **Keywords:** Ginkgo Biloba Extract (GBE), Acute Mountain Sickness (AMS)  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 44 **Ginkgo Biloba Extract for Prevention of Acute Mountain Sickness: A Systematic** 45 46 **Review and Meta-analysis of Randomized Controlled Trials**

### 47 **Abstract**

#### 48 **Study objective:**

49  
50  
51  
52 Trials of ginkgo biloba extract (GBE) for the prevention of acute mountain sickness  
53  
54 (AMS) have been published since 1996. Because of their conflicting results, the  
55  
56  
57  
58  
59  
60

1  
2  
3 efficacy of GBE remains unclear. We performed a systematic review and meta-  
4  
5 analysis to assess whether GBE prevents acute mountain sickness.  
6

7  
8 **Methods:**

9  
10 The Cochrane Library, EMBASE, Google Scholar, and PubMed databases were  
11  
12 searched for articles published up to May 20, 2017. Only randomized controlled trials  
13  
14 were included. The main outcome measures were the relative risks of AMS in  
15  
16 participants receiving GBE for prophylaxis. Meta-analyses were conducted using  
17  
18 random-effects models. Sensitivity analyses and tests for publication bias were  
19  
20 conducted.  
21  
22

23  
24 **Results:**

25  
26 Six published articles with a total of 487 participants met all eligibility criteria. The  
27  
28 pooled result found that GBE did not prevent AMS (relative risk =0.86; 95% CI: 0.45  
29  
30 to 1.04; p-value=0.07). The results of subgroup analyses of studies with low risk of  
31  
32 bias, low starting altitude (<2500 m), and different starting treatments prior to  
33  
34 ascent were similar.  
35  
36

37  
38 **Conclusions:** The currently available data suggest that GBE does not prevent AMS  
39  
40 regardless of starting altitude and pre-ascent starting treatment.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

## Background

Rapid ascent from low to high altitude (> 2500 m above the sea level) is often followed by headache, fatigue, shortness of breath, sleeplessness, and anorexia, a symptom complex called acute mountain sickness (AMS).<sup>1</sup> AMS is more likely to happen at altitudes higher than 2500 m,<sup>2</sup> and worldwide studies reported incidences of AMS of 25–37% at 1900–3400 m.<sup>1,3</sup> Children are more prone to develop AMS, with an incidence of 59%.<sup>4</sup>

The pathophysiology of AMS is associated with cerebral edema, with the most compelling evidence coming from the brain MRI study of Hackett et al.,<sup>5</sup> which showed intense T2 signals in the white matter, particularly in the splenium and corpus callosum. Vasogenic leakage increases permeability of the endothelium, causing an elevation in intravascular pressures and inducing hypoxemia. In addition, hypoxic ventilatory response and activation of the renin-angiotensin–aldosterone system are also reported to be associated with AMS.<sup>6</sup> The most effective method to prevent AMS is gradual ascent. The most common pharmacologic agent used to prevent AMS is acetazolamide.<sup>7</sup> However, acetazolamide can cause paresthesias, dysgeusia, and sometimes nausea or drowsiness.<sup>8</sup> Its use is also contraindicated in patients with a history of anaphylaxis to sulfa antibiotics or acetazolamide.

## Importance

Ginkgo biloba extract (GBE) is an option for those seeking a natural alternative treatment. Roncin et al. in 1996 published the first studies to suggest that GBE can prevent AMS.<sup>9</sup> However, not all subsequent studies have shown benefit.<sup>10-15</sup> To date, there is no best evidence to support the effectiveness of GBE.

## Goals of This Investigation

Our study aim was to assess the effectiveness of GBE in prophylaxis of AMS by conducting a meta-analysis and systematic review of the relevant literature.

## Methods

### Databases and search strategy

We searched the Cochrane Library, EMBASE, Google Scholar, and PubMed databases for articles published up to May 20<sup>th</sup>, 2017. No limits were applied to our Boolean search strategy, which included keywords ('Ginkgo', 'Altitude Sickness', 'Mountain'), Medical Subject Headings (MeSH) ('Ginkgo biloba', 'Altitude Sickness'), and Emtree terms ('Ginkgo biloba', 'altitude disease'). References from retrieved articles were also examined to identify other relevant articles.

Studies were included in the systematic review if they were (1) randomized controlled trials (RCTs) of GBE for prevention of AMS; (2) compared GBE with placebo; and (3) conducted in humans. Studies were excluded if they were irrelevant to the study's aim, were animal studies, lacked a placebo group, or were published as review articles, case reports, editorials, or letters. The Institutional Review Board of Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan, approved the protocol.

### Data extraction and assessment of methodological quality

Two reviewers (TYT and YCS) independently screened titles and abstracts of all articles identified by the search strategy. Inter-reviewer disagreements concerning the inclusion or exclusion of a study were resolved by consensus and, if necessary, consultation with a third reviewer (SHW).



1  
2  
3 The Cochrane Collaboration's tool was used to assess the risk of selection,  
4 performance, detection, attrition, and reporting biases in the included randomized  
5 trials.<sup>16</sup> All co-authors discussed and made the final decisions about the overall risk  
6 of bias in the included trials. If data were not readily available or clear, we contacted  
7 first authors and corresponding authors to get further information. If studies were  
8 found to be at high risk of bias, meta-analyses stratified by study quality were  
9 performed.

10 Both reviewers independently extracted data from the articles selected for inclusion.  
11 The extracted data included the name of the first author, year of publication,  
12 numbers of participants, gender, starting and final altitudes, AMS scoring definitions,  
13 prescriptions of GBE, days of treatment prior to ascent, and number of individuals  
14 with AMS in the treatment and control groups.

### 15 **Data collection, data processing, and primary data analysis**

16 Pooled relative risk (RR) with corresponding 95% confidence intervals (CIs) for each  
17 outcome of interest were calculated. The main outcome measure was the RR of AMS  
18 in participants receiving GBE for prophylaxis. Random effect models were selected  
19 for these analyses.

20 We conducted subgroup analyses based on quality of studies, number of  
21 treatment days before ascending, and starting altitude below 2500 m.<sup>17 18</sup> Between-  
22 study heterogeneity was evaluated with the  $I^2$  statistic.<sup>19</sup> Funnel plots, the Egger  
23 regression asymmetry test, and Begg adjusted rank correlation test were applied for  
24 assessment of potential publication bias.<sup>20 21</sup> We also conducted sensitivity analysis  
25 to evaluate the influence of each study on the overall pooled estimate. Analyses

1  
2  
3 were all conducted using STATA version 11.0 (StataCorp, College Station, Texas, USA).

4  
5 All statistical tests were two-sided and were considered significant when the P value  
6  
7 was 0.05 or less.  
8  
9

## 10 11 12 **Results**

13 The literature search and study selection process are summarized in Figure 1.  
14  
15 After the exclusion of duplicate studies, non-relevant studies, and other studies that  
16  
17 met exclusion criteria based on a screening of article titles and abstracts, 38  
18  
19 potentially relevant studies were retrieved for full review.  
20  
21

22 One publication was retrieved by hand search of the references. In this study,  
23  
24 Wang et al.<sup>22</sup> compared the prophylactic effect of GBE with that of other Chinese  
25  
26 medications on AMS. However, the study had no placebo group design<sup>23</sup> and had to  
27  
28 be excluded from our meta-analysis.  
29  
30

31 In the randomized double-blind study by Kè in 2013,<sup>15</sup> AMS was reported as a  
32  
33 secondary outcome and the number of events in each group were not reported. We  
34  
35 contacted the first and corresponding authors by email but (as of October 9, 2017)  
36  
37 received no response. Since the published data could not be included for analysis, we  
38  
39 excluded this study.  
40  
41

42 Six published articles met all eligibility criteria after a careful review process.<sup>9-14</sup>  
43  
44 In the article published by Leadbetter et al.,<sup>14</sup> two randomized controlled trials were  
45  
46 conducted. As a result, a total of 7 study groups with 487 participants were enrolled.  
47  
48 The characteristics of these studies and the participants are listed in Table 1. Four  
49  
50 study groups<sup>9 10 13 14</sup> demonstrated the efficacy of GBE in preventing AMS, while  
51  
52 three<sup>11 12 14</sup> did not. All studies had small numbers of subjects except the one by  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Gertsch and colleagues.<sup>11</sup> Of note, participants in the study conducted by Gertsch et  
4 al., and published in 2004, started GBE treatment at high altitude (4280–4358 m),  
5 which was different from the other studies. Further information such as study  
6 dosage, prescription frequency, number of days prior to ascending, and source of  
7 GBE are summarized in Table 2. The number of AMS events is given in Table 3. The  
8 evidence quality of these studies as assessed by Cochrane Collaboration's tool is  
9 presented in Table 4. Two of 6 articles were not double-blinded and both of them  
10 included male participants only.<sup>9,13</sup>

11  
12 In the primary meta-analysis of all 7 study groups, GBE did not prevent AMS (RR  
13 =0.86; 95% CI: 0.45 to 1.04; p-value=0.07) (Figure 2). The I<sup>2</sup> statistic was 58.7% (p-  
14 value=0.02), indicating substantial heterogeneity. After excluding two high-risk-bias  
15 studies,<sup>9,13</sup> the I<sup>2</sup> statistic became 39.7% (p-value=0.16) and the result did not change  
16 (RR =0.79; 95% CI 0.58 to 1.08; p-value=0.144) (Figure 3). The funnel plot did not  
17 demonstrate asymmetry (Figure 4). The Egger's-test and Begg-test p values (0.178  
18 and 0.462, respectively) indicate the absence of statistical evidence of publication  
19 bias after excluding our presumed high-risk-bias articles.

20  
21 Sensitivity analysis was conducted by removing one trial at a time to determine  
22 what influence each low-risk bias study had on the pooled analysis. The pooled result  
23 seemed to be robust. For example, removing the study 1 conducted by Leadbetter et  
24 al. in 2009<sup>14</sup> only changed the pooled estimate from 0.79 to 0.88 (95% CI 0.66–1.17;  
25 P value=0.38; Figure 5).

26  
27 The results of several pre-planned subgroup analyses with all 7 datasets were  
28 similar. Excluding the study by Gertsch and colleagues in 2004,<sup>11</sup> GBE was not  
29 prophylactic when the starting altitude was below 2500 m (RR =0.56; 95% CI 0.31 to  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 1.01; Figure 6). Regarding the number of days of treatment prior to ascent, GBE was  
4  
5 not prophylactic when given “3–5 days prior to ascent” (RR =0.72; 95% CI 0.41 to  
6  
7 1.26; Figure 7) or “0–2 days prior to ascent” (RR =0.56; 95% CI 0.25 to 1.25; Figure 8).  
8  
9

## 10 11 12 **Limitations**

13  
14 Our systematic review has several limitations. First, to limit the influence of study  
15  
16 biases on pooled evaluation, we decided to only include RCTs. However, there were  
17  
18 few RCTs in this field. Moreover, only 4 of 6 RCTs were double-blinded. Second,  
19  
20 because of the difficulty in carrying out high altitude medicine studies, many studies  
21  
22 involved only a small number of cases. In our primary pooled analysis, a total of 487  
23  
24 participants were enrolled. Insufficient power may be an issue even in the meta-  
25  
26 analysis. Third, the participants were predominantly adult males and whether there  
27  
28 is gender or age difference between treatment (GBE vs placebo) groups or response  
29  
30 (no AMS vs AMS) groups is unknown. Fourth, GBE is a complex mixture of natural  
31  
32 components. It is difficult to standardize all components. A lack of consistency  
33  
34 between commercially available GBE preparations may explain these differing  
35  
36 results. Finally, differences between studies in factors such as the strength, rate of  
37  
38 ascent, and other characteristics of participants may also account for inconsistent  
39  
40 results.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

To our knowledge, this is the first meta-analysis of RCTs evaluating GBE as an AMS prophylactic. In pooled analyses, we found that although GBE may tend toward AMS prophylaxis, it had no statistically significant prophylactic effect (RR =0.86; 95% CI: 0.45 to 1.04; p-value=0.07). The results of several subgroup analyses were similar. GBE also failed to show benefits in preventing AMS in low-risk bias studies, studies in which the starting altitude was low, and studies differing in the initial treatment regimen prior to ascent.

The effectiveness of GBE in AMS prophylaxis has been reported.<sup>9 10 13 14</sup> Zhang and colleagues in 2003 reported that GBE was the most effective of six Chinese medicines tested for AMS prophylaxis.<sup>23</sup> GBE has been used primarily for the treatment of dementias (e.g., Alzheimer's disease), peripheral vascular diseases (e.g., intermittent claudication), and neurosensory problems (e.g., tinnitus).<sup>24</sup> Hypotheses have been proposed to explain the possible role that GBE plays in preventing AMS. Hypoxia is a common feature of AMS. Several studies have suggested that nitric oxide (NO) may play a pathogenic role in AMS by mediating hypoxia-induced cerebral vasodilation in humans.<sup>13 25 26</sup> GBE was found to be an NO scavenger. NO scavenging can result in decreased intracellular NO level.<sup>27</sup> Furthermore, GBE may inhibit phosphodiesterase activity, thus enhancing relaxation of parietal smooth muscle cells and so lead to vasodilation of parietal vessels. Vasodilation in turn increases tissue perfusion and decreases local hypoxia.<sup>27</sup> Other potential mechanisms include increasing endogenous antioxidants,<sup>28</sup> reducing free-radical production,<sup>29</sup> and reducing lung leak during hypoxia.<sup>30</sup> GBE was also shown to prevent high altitude pulmonary edema in a rat model.<sup>31</sup>

1  
2  
3 On the other hand, several studies failed to demonstrate the benefit of GBE in  
4 AMS prophylaxis.<sup>11 12 15</sup> The duration of therapy before ascent and differences in the  
5 altitude at which GBE is initiated may account for the conflicts between trial results.  
6  
7 To test these hypotheses, we conducted subgroup analyses and obtained similar  
8 results to those obtained with the original pooled data. Another explanation for the  
9 differences in efficacy may be variation in the GBE composition. For instance,  
10 Leadbetter and colleagues in 2009 compared GBE from two different sources and  
11 found they differed in composition as well as ability to reduce the incidence and  
12 severity of AMS following rapid ascent to high altitude.<sup>14</sup> The German Federal  
13 Institute for Drugs and Medicinal Devices Commission E recommends similar  
14 specifications for standardization of GBE. All included studies used GBE that met the  
15 German E commission standard, but most of studies use products from different  
16 companies. As an herbal supplement, more than 60% of GBE component is not  
17 mandated by law and composition may vary considerably between manufacturers. A  
18 lack of bioequivalence has been noted between brands of GBE.<sup>32 33</sup>

## 37 Conclusion

38  
39 In the present systematic review and meta-analysis of the currently available data  
40 sources, we found that GBE may not prevent AMS. Furthermore, subgroup analysis  
41 of low-risk bias studies, studies with low starting altitude, and studies with different  
42 starting treatment regimens prior to ascent, also indicated that GBE does not prevent  
43 AMS.  
44  
45  
46  
47  
48  
49  
50

## 51 Table and Figure Legends

52  
53 Figure 1. Trial selection algorithm

54  
55 Figure 2. Forest plot: Effect of GBE in prevention of acute mountain sickness.  
56  
57  
58  
59  
60

1  
2  
3 Figure 3. Forest plot: Effect of GBE in prevention of acute mountain sickness in low-  
4 risk-bias studies

5  
6  
7 Figure 4. Funnel plot of low bias studies

8  
9  
10 Figure 5. Sensitivity analyses by removing one trial at a time in low-risk-bias studies

11  
12 Figure 6. Forest plot of subgroup meta-analysis: studies starting altitude was below  
13 2500m

14  
15  
16 Figure 7. Forest plot of subgroup meta-analysis: studies starting treatment 3-5 days  
17 prior to ascent

18  
19  
20 Figure 8. Forest plot of subgroup meta-analysis: studies starting treatment 0-2 days  
21 prior to ascent

22  
23  
24 Table 1. Characteristics of included studies

25  
26  
27 Table 2. Characteristics of included studies, sources, dosage and duration of GBE

28  
29  
30 Table 3. Events of acute mountain sickness between placebo and GBE

31  
32  
33 Table 4. Risk of bias in included studies.

### 34 35 **Declarations**

### 36 37 **Consent for publication**

38  
39  
40 Not applicable

### 41 42 **Competing interests**

43  
44  
45 The authors declare that they have no competing interests in this section.

### 46 47 **Exclusive licence**

48  
49  
50 The Corresponding Author has the right to grant on behalf of all authors and does  
51 grant on behalf of all authors, a worldwide licence

52  
53  
54 (<http://www.bmj.com/sites/default/files/BMJ%20Author%20Licence%20March%20>

55  
56  
57 013.doc) to the Publishers and its licensees in perpetuity, in all forms, formats and

1  
2  
3 media (whether known now or created in the future), to i) publish, reproduce,  
4  
5 distribute, display and store the Contribution, ii) translate the Contribution into other  
6  
7 languages, create adaptations, reprints, include within collections and create  
8  
9 summaries, extracts and/or, abstracts of the Contribution and convert or allow  
10  
11 conversion into any format including without limitation audio, iii) create any other  
12  
13 derivative work(s) based in whole or part on the on the Contribution, iv) to exploit all  
14  
15 subsidiary rights to exploit all subsidiary rights that currently exist or as may exist in  
16  
17 the future in the Contribution, v) the inclusion of electronic links from the  
18  
19 Contribution to third party material where-ever it may be located; and, vi) licence  
20  
21 any third party to do any or all of the above. All research articles will be made  
22  
23 available on an Open Access basis (with authors being asked to pay an open access  
24  
25 fee—see [http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-](http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse)  
26  
27 [checklists/copyright-open-access-and-permission-reuse](http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse)). The terms of such Open  
28  
29 Access shall be governed by a Creative Commons licence—details as to which  
30  
31 Creative Commons licence will apply to the research article are set out in our  
32  
33 worldwide licence referred to above.  
34  
35  
36  
37  
38

### 39 **Authors' contributions**

40  
41  
42 TYT analyzed and interpreted the data and was a major contributor in writing the  
43  
44 manuscript. SHW interpreted the data. YKL supervised the study and interpreted the  
45  
46 data. YCS analyzed the data and contribute in the manuscript formation. All authors  
47  
48 read and approved the final manuscript.  
49

### 50 **Transparency declaration**

51  
52  
53 We affirm that the manuscript is an honest, accurate, and transparent account of the  
54  
55 study being reported; that no important aspects of the study have been omitted; and  
56  
57  
58  
59



1  
2  
3 that any discrepancies from the study as planned (and, if relevant, registered) have  
4  
5 been explained.  
6  
7

## 8 9 **References**

- 10  
11 1. Honigman B, Theis MK, Koziol-McLain J, et al. Acute mountain sickness in a general  
12 tourist population at moderate altitudes. *Annals of internal medicine* 1993;**118**(8):587-92.
- 13  
14 2. Basnyat B, Murdoch DR. High-altitude illness. *Lancet* (London, England)  
15 2003;**361**(9373):1967-74.
- 16  
17 3. Shih-Hao Wang Y-CC, Wei-Fong Kao, Yu-Jr Lin, Jih-Chang Chen, Te-Fa Chiu, Tai-Yi  
18 Hsu, Hang-Cheng Chen, Shih-Wei Liu. Epidemiology of Acute Mountain  
19 Sickness on Jade Mountain, Taiwan: An Annual Prospective Observational  
20 Study. *High Altitude Medicine & Biology* 2010;**11**(1):43-49.
- 21  
22 4. Chan CW, Lin YC, Chiu YH, et al. Incidence and risk factors associated with acute  
23 mountain sickness in children trekking on Jade Mountain, Taiwan. *Journal of*  
24 *travel medicine* 2016;**23**(1).
- 25  
26 5. Hackett PH, Yarnell PR, Hill R, et al. High-altitude cerebral edema evaluated with  
27 magnetic resonance imaging: clinical correlation and pathophysiology. *Jama*  
28 1998;**280**(22):1920-5.
- 29  
30 6. Schoene RB. Illnesses at high altitude. *Chest* 2008;**134**(2):402-16.
- 31  
32 7. Zafren K. Prevention of high altitude illness. *Travel Medicine and Infectious Disease*  
33 2014;**12**(1):29-39.
- 34  
35 8. Seupaul RA, Welch JL, Malka ST, et al. Pharmacologic prophylaxis for acute  
36 mountain sickness: a systematic shortcut review. *Ann Emerg Med*  
37 2012;**59**(4):307-17.e1.
- 38  
39 9. Roncin JP, Schwartz F, D'Arbigny P. EGB 761 in control of acute mountain sickness  
40 and vascular reactivity to cold exposure. *Aviation, space, and environmental*  
41 *medicine* 1996;**67**(5):445-52.
- 42  
43 10. Gertsch JH, Seto TB, Mor J, et al. Ginkgo biloba for the prevention of severe acute  
44 mountain sickness (AMS) starting one day before rapid ascent. *High altitude*  
45 *medicine & biology* 2002;**3**(1):29-37.
- 46  
47 11. Gertsch JH, Basnyat B, Johnson EW, et al. Randomised, double blind, placebo  
48 controlled comparison of ginkgo biloba and acetazolamide for prevention of  
49 acute mountain sickness among Himalayan trekkers: the prevention of high  
50 altitude illness trial (PHAIT). *BMJ (Clinical research ed)* 2004;**328**(7443):797.
- 51  
52 12. Chow T, Browne V, Heilesen HL, et al. Ginkgo biloba and acetazolamide  
53 prophylaxis for acute mountain sickness: a randomized, placebo-controlled  
54 trial. *Archives of internal medicine* 2005;**165**(3):296-301.
- 55  
56 13. Moraga FA, Flores A, Serra J, et al. Ginkgo biloba decreases acute mountain  
57 sickness in people ascending to high altitude at Ollagüe (3696 m) in Northern  
58 Chile. *Wilderness and Environmental Medicine* 2007;**18**(4):251-57.
- 59  
60 14. Leadbetter G, Keyes LE, Maakestad KM, et al. Ginkgo biloba does--and does not--  
prevent acute mountain sickness. *Wilderness & environmental medicine*  
2009;**20**(1):66-71.

15. Ke T, Wang J, Swenson ER, et al. Effect of acetazolamide and ginkgo biloba on the human pulmonary vascular response to an acute altitude ascent. *High altitude medicine & biology* 2013;**14**(2):162-7.
16. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ (Clinical research ed)* 2011;**343**:d5928.
17. Hackett PH, Roach RC. High-Altitude Illness. *New England Journal of Medicine* 2001;**345**(2):107-14.
18. van Patot MC, Keyes LE, Leadbetter G, 3rd, et al. Ginkgo biloba for prevention of acute mountain sickness: does it work? *High altitude medicine & biology* 2009;**10**(1):33-43.
19. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ (Clinical research ed)* 2003;**327**(7414):557-60.
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;**50**(4):1088-101.
21. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical research ed)* 1997;**315**(7109):629-34.
22. Wang J, Xiong X, Xing Y, et al. Chinese herbal medicine for acute mountain sickness: A systematic review of randomized controlled trials. *Evidence-based Complementary and Alternative Medicine* 2013;**2013**.
23. X. Z. Zhang HJY, Z. D. Ha et al. Role of six different medicines in the symptomatic scores of benign form of acute mountain sickness. *Medical Journal of National Defending Forces in Northwest China* 2003;**24**(5):341-43.
24. Sierpina VS, Wollschlaeger B, Blumenthal M. Ginkgo biloba. *Am Fam Physician* 2003;**68**(5):923-6.
25. Roach RC, Hackett PH. Frontiers of hypoxia research: acute mountain sickness. *The Journal of experimental biology* 2001;**204**(Pt 18):3161-70.
26. Van Mil AH, Spilt A, Van Buchem MA, et al. Nitric oxide mediates hypoxia-induced cerebral vasodilation in humans. *Journal of applied physiology (Bethesda, Md : 1985)* 2002;**92**(3):962-6.
27. Marcocci L, Maguire JJ, Droy-Lefaix MT, et al. The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761. *Biochemical and biophysical research communications* 1994;**201**(2):748-55.
28. Louajri A, Harraga S, Godot V, et al. The effect of ginkgo biloba extract on free radical production in hypoxic rats. *Biological & pharmaceutical bulletin* 2001;**24**(6):710-2.
29. Naik SR, Pilgaonkar VW, Panda VS. Evaluation of antioxidant activity of Ginkgo biloba phytosomes in rat brain. *Phytotherapy research : PTR* 2006;**20**(11):1013-6.
30. Liu K-X, Wu W-K, He W, et al. Ginkgo biloba extract (EGb 761) attenuates lung injury induced by intestinal ischemia/reperfusion in rats: Roles of oxidative stress and nitric oxide. *World Journal of Gastroenterology : WJG* 2007;**13**(2):299-305.
31. Berg JT. Ginkgo biloba extract prevents high altitude pulmonary edema in rats. *High altitude medicine & biology* 2004;**5**(4):429-34.
32. De Smet PA. Herbal remedies. *The New England journal of medicine* 2002;**347**(25):2046-56.

33. Kressmann S, Muller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba brands. *The Journal of pharmacy and pharmacology* 2002;**54**(5):661-9.

**Table 1.** Characteristics of included studies.

	Participants (number)	Male (%)	Starting altitude (m)	Altitude reached (m)	AMS scoring
<b>GBE prevented acute mountain sickness</b>					
Roncin, 1996	44	100	1,800	5,400	AMS-C >0.7, raw mean scores
Gertsch, 2002	26	46	0	4,205	LLS ≥3 with HA, LLS severity
Moraga, 2007	24	100	0	3,696	LLS ≥3, or 1 symptom ≥3
Leadbetter, 2009 Study 1	40	45	2,000	4,300	AMS-C ≥0.7 plus LLS ≥3 with HA
<b>GBE did not prevent acute mountain sickness</b>					
Leadbetter, 2009 Study 2	37	44	2,000	4,300	AMS-C ≥0.7 + LLS ≥3 with HA
Gertsch, 2004	279	70	4,280– 4,358	4,928	LLS ≥3 with HA
Chow, 2005	37	54	1,230	3,800	LLS ≥3 with HA

GBE: ginkgo biloba extract; AMS: Acute mountain sickness; AMS-C: the Environmental Symptom Questionnaire III acute mountain sickness-cerebral (AMS-C) score; HA: headache; LLS: Lake Louise Score.

**Table 2.** Characteristics of included studies, sources, dosage and duration of ginkgo biloba.

	GBE source	Dose	Days of treatment prior to ascent
<b>GBE prevented acute mountain sickness</b>			
Roncin, 1996	Tanakan® DCI: EGb 761 Ipsen, Paris, France	60 mg BID	0
Gertsch, 2002	GK501 Memfit ®, EGb 761, Pharmaton EGb 761	60 mg TID	1
Moraga, 2007	Rokan, Andromeco Laboratories, Chile	80 mg BID	1
Leadbetter, 2009 Study 1	Spectrum Quality, Laboratories Products, Inc.	120 mg BID	4
<b>GBE did not prevent acute mountain sickness</b>			
Leadbetter, 2009 Study 2	Technical Sourcing, Inc. GK501	120 mg BID	3
Gertsch, 2004	International, Pharmaton <i>Ginkgo biloba</i> 120 mg	120 mg BID	1–2
Chow, 2005	Vegetarian NOW® Foods	120 mg BID	5

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BID: Bi in die=twice a day; TID: ter in die=three times a day.

For peer review only

**Table 3.** Events of acute mountain sickness compared between placebo and

ginkgo biloba.

	Placebo		GBE	
	AMS	All subjects	AMS	All subjects
<b>GBE prevented acute mountain sickness</b>				
Roncin, 1996	9	22	0	22
Gertsch, 2002	13	14	7	12
Moraga, 2007	7	12	0	12
Leadbetter, 2009 Study 1	13	19	7	21
<b>GBE did not prevent acute mountain sickness</b>				
Leadbetter, 2009 Study 2	10	22	4	15
Gertsch, 2004	40	119	43	124
Chow, 2005	12	20	11	17

**Table 4.** Risk of bias in included studies.

Risk of bias domain	Roncin, 1996	Gertsch, 2002	Gertsch, 2004	Chow, 2005	Moraga, 2007	Leadbetter, 2009
Random-sequence generation (selection bias)	Unclear	Low	Low	Low	Low	Low
Allocation concealment (selection bias)	Unclear	Low	Low	Low	Unclear	Low
Blinding of participants (performance bias)	High	Low	Low	Low	High	Low
Blinding of outcome assessment (detection bias)	High	Low	Low	Low	High	Low
Incomplete outcome data (attrition bias)	High	Low	Low	Low	Low	Low
Selective outcome reporting (reporting bias)	Low	Low	Low	Low	Low	Low
Other source of bias	High	Low	High	Low	High	Low
<b>Overall risk of bias</b>	<b>High</b>	<b>Low</b>	<b>Low</b>	<b>Low</b>	<b>High</b>	<b>Low</b>





Figure 1

190x142mm (300 x 300 DPI)




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



209x147mm (300 x 300 DPI)

new only


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



215x145mm (300 x 300 DPI)


view only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



199x145mm (300 x 300 DPI)


Pre-view only



304x170mm (300 x 300 DPI)

review only


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



212x145mm (300 x 300 DPI)

Review only


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



215x148mm (300 x 300 DPI)

Review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



204x135mm (300 x 300 DPI)

view only



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N.A.
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	6





# PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	5
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	8
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	9
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	9
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	11
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	N.A.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## Ginkgo Biloba Extract for Prevention of Acute Mountain Sickness: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022005.R1
Article Type:	Research
Date Submitted by the Author:	27-Apr-2018
Complete List of Authors:	Tsai, Tou-Yuan ; Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, Emergency Department WANG, SHIH-HAO; Chang Gung Memorial Hospital at Chiayi, Department of Physical Medicine and Rehabilitation Lee, Yi-Kung; Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, Emergency Department Su, Yung-Cheng; Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, Emergency Department
<b>Primary Subject Heading</b>:	Sports and exercise medicine
Secondary Subject Heading:	Emergency medicine, Occupational and environmental medicine
Keywords:	Ginkgo Biloba Extract, Acute Mountain Sickness, meta-analysis

SCHOLARONE™  
Manuscripts

Only

1  
2  
3 **Ginkgo Biloba Extract for Prevention of Acute Mountain Sickness: A Systematic Review and**  
4  
5 **Meta-analysis of Randomized Controlled Trials**  
6

7 Tou-Yuan Tsai, MD<sup>1,2</sup>; Shih-Hao Wang, MD<sup>2-5</sup>; Yi-Kung Lee, MD, MPH<sup>1,2</sup>; and Yung-Cheng Su,  
8  
9 MD, MPH.<sup>1,2</sup>  
10

11 **Institutions:**  
12

13  
14 <sup>1</sup>School of Medicine, Tzu Chi University, Hualien, Taiwan  
15

16 <sup>2</sup>Emergency Department, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation,  
17  
18 Chiayi, Taiwan  
19

20  
21 <sup>3</sup>Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at  
22  
23 Chiayi, Chiayi, Taiwan.  
24

25  
26 <sup>4</sup>Department of Recreation and Leisure Industry Management, College of Management,  
27  
28 National Taiwan Sport University, Taoyuan, Taiwan.  
29

30 <sup>5</sup>Taiwan Wilderness Medical Association, New Taipei City, Taiwan.  
31  
32  
33  
34

35 **Reprints and correspondence:**  
36

37 Yung-Cheng Su, MD, MPH.  
38

39 Emergency Department  
40

41 Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation  
42

43  
44 No. 2, Minsheng Rd., Dalin Township  
45

46 Chiayi County 622, Taiwan (R.O.C.)  
47

48  
49 Tel: 886-5-2648000 ext 5838  
50

51 Fax: 886-5-2648499  
52

53 E-mail: [drs119@gmail.com](mailto:drs119@gmail.com)  
54

55 **Running title:** Ginkgo Biloba Extract for Acute Mountain Sickness  
56  
57  
58  
59  
60

**Word count:**

Abstract: 241 words

Full text: 2248 words

**Number of references: 36****Number of tables: 3****Number of figures: 2****Number of supplementary files: 3****Author Disclosures:**

Dr. Tou-Yuan Tsai reports no disclosures.

Dr. Shih-Hao Wang reports no disclosures.

Dr. Yi-Kung Lee reports no disclosures.

Dr. Yung-Cheng Su reports no disclosures.

**Email address:**

Dr. Tou-Yuan Tsai: 96311123@gms.tcu.edu.tw

Dr. Shih-Hao Wang: mountainwangsh@gmail.com

Dr. Yi-Kung Lee: lyg1968@seed.net.tw

Dr. Yung-Cheng Su: [drsu119@gmail.com](mailto:drsu119@gmail.com)

**Author contributions:**

TYT analyzed and interpreted the data and was a major contributor in writing the manuscript. SHW interpreted the data. YKL supervised the study and interpreted the data. YCS interpreted the data and wrote the manuscript. All authors read and approved the final manuscript.

**Funding**

The authors did not receive any funding for this study.

### Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

**Keywords:** Ginkgo Biloba Extract (GBE), Acute Mountain Sickness (AMS)

For peer review only

**Abstract****Study objective:**

Trials of ginkgo biloba extract (GBE) for the prevention of acute mountain sickness (AMS) have been published since 1996. Because of their conflicting results, the efficacy of GBE remains unclear. We performed a systematic review and meta-analysis to assess whether GBE prevents acute mountain sickness.

**Methods:**

The Cochrane Library, EMBASE, Google Scholar, and PubMed databases were searched for articles published up to May 20, 2017. Only randomized controlled trials were included. AMS defined as acute mountain sickness–cerebral(AMS-C) score  $\geq 0.7$  or Lake Louise Score (LLS)  $\geq 3$  with headache. The main outcome measures were the relative risks of AMS in participants receiving GBE for prophylaxis. Meta-analyses were conducted using random-effects models. Sensitivity analyses, subgroup analyses and tests for publication bias were conducted.

**Results:**

Six published articles with a total of 451 participants met all eligibility criteria. In the primary meta-analysis of all 7 study groups, GBE showed trend of AMS prophylaxis, but it is not statistically significant (RR =0.68; 95% CI: 0.45 to 1.04; p-value=0.08). The  $I^2$  statistic was 58.7% (p-value=0.02), indicating substantial heterogeneity. The results of subgroup analyses of studies with low risk of bias, low starting altitude (<2500 m), number of treatment days before ascending and dosage of GBE were similar.

**Conclusions:**

The currently available data suggest that although GBE may tend toward AMS prophylaxis, there are not enough data to show the statistically significant effect of GBE for preventing

AMS. Further large randomized control studies are warranted.

### Strengths and limitations of this study

- This study is, to date, the first systematic review and meta-analysis evaluating Ginkgo Biloba Extract (GBE) as an Acute Mountain Sickness (AMS) prophylactic, strengthened by a thorough quality assessment of each enrolled study and comprehensive subgroup analyses.
- In the pooled analyses, although GBE may tend toward AMS prophylaxis, it is not statistically significant. Subgroup analyses of low-risk bias studies, studies with low starting altitude, number of treatment days before ascending and dosage of GBE also revealed the similar results.
- Insufficient power may be an issue in this meta-analysis. Further large randomized control studies are warranted.

## Introduction

### Background

Rapid ascent from low to high altitude (> 2500 m above the sea level) is often followed by headache, fatigue, shortness of breath, sleeplessness, and anorexia, a symptom complex called acute mountain sickness (AMS).<sup>1</sup> Lake Louise Score (LLS) Questionnaires<sup>2</sup> and Environmental Symptom Questionnaire III<sup>3</sup> are two tools to diagnose and evaluate severity of AMS. AMS is more likely to happen at altitudes higher than 2500 m,<sup>4</sup> and worldwide studies reported incidences of AMS of 25–37% at 1900–3400 m.<sup>1,5</sup> Children are more prone to develop AMS, with an incidence of 59%.<sup>6</sup>

The pathophysiology of AMS is associated with cerebral edema, with the most

1  
2  
3 compelling evidence coming from the brain MRI study of Hackett et al.,<sup>7</sup> which showed  
4  
5 intense T2 signals in the white matter, particularly in the splenium and corpus callosum.  
6  
7 Vasogenic leakage increases permeability of the endothelium, causing an elevation in  
8  
9 intravascular pressures and inducing hypoxemia. In addition, hypoxic ventilatory response  
10  
11 and activation of the renin-angiotensin–aldosterone system are also reported to be  
12  
13 associated with AMS.<sup>8</sup> The most effective method to prevent AMS is gradual ascent. The  
14  
15 most common pharmacologic agent used to prevent AMS is acetazolamide.<sup>9</sup> However,  
16  
17 acetazolamide can cause paresthesia, dysgeusia, and sometimes nausea or drowsiness.<sup>10</sup> Its  
18  
19 use is also contraindicated in patients with a history of anaphylaxis to sulfa antibiotics or  
20  
21 acetazolamide.  
22  
23  
24

## 25 26 **Importance**

27  
28 Ginkgo biloba extract (GBE) is an option for those seeking a natural alternative  
29  
30 treatment. GBE is found to decrease the tissue hypoxia, induces vasodilation, reduces free-  
31  
32 radical production and lung leak, which may in turn prevent AMS.<sup>11-14</sup> Roncin et al. in 1996  
33  
34 published the first studies to suggest that GBE can prevent AMS.<sup>15</sup> However, not all  
35  
36 subsequent studies have shown benefit.<sup>13 16-20</sup> To date, there is no best evidence to support  
37  
38 the effectiveness of GBE.  
39  
40  
41

## 42 **Goals of This Investigation**

43  
44 Our study aim was to assess the effectiveness of GBE in prophylaxis of AMS by  
45  
46 conducting a meta-analysis and systematic review of the relevant literature.  
47  
48  
49  
50

## 51 **Methods**

### 52 **Databases and search strategy**

53  
54 We searched the Cochrane Library, EMBASE, Google Scholar, and PubMed databases for  
55  
56  
57  
58  
59  
60



1  
2  
3 articles published up to May 20<sup>th</sup>, 2017. No limits were applied to our Boolean search  
4  
5 strategy, which included keywords ('Ginkgo', 'Altitude Sickness', 'Mountain'), Medical Subject  
6  
7 Headings (MeSH) ('Ginkgo biloba', 'Altitude Sickness'), and Emtree terms ('Ginkgo biloba',  
8  
9 'altitude disease'). References from retrieved articles were also examined to identify other  
10  
11 relevant articles.  
12

13  
14 Studies were included in the systematic review if they were (1) randomized controlled  
15  
16 trials (RCTs) of healthy non-acclimatized adult between age 18 and 60 years; (2) compared  
17  
18 GBE with placebo; (3) conducted in humans; and (4) studies diagnosing AMS with the Lake  
19  
20 Louise Score or AMS-C. We excluded studies which subjects were pregnant, had symptoms  
21  
22 consistent with AMS at baseline. Studies were also excluded if they were irrelevant to the  
23  
24 study's aim, were animal studies, lacked a placebo group, or were published as review  
25  
26 articles, case reports, editorials, or letters. The systematic review and the meta-analysis was  
27  
28 conducted under the PRISMA guidelines (see online supplementary Checklist). The  
29  
30 Institutional Review Board of Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation,  
31  
32 Taiwan, approved the protocol.  
33  
34  
35

### 36 37 **Outcome measures**

38  
39 AMS defined as AMS-C score  $\geq 0.7$  or an LLS  $\geq 3$  with headache. Primary outcome were the  
40  
41 relative risks of AMS in participants receiving GBE for prophylaxis. Secondary outcomes in  
42  
43 the enrolled studies are summarized as the supplementary table. We only extracted data  
44  
45 when they were available in dichotomous form.  
46  
47

### 48 49 **Data extraction and assessment of methodological quality**

50  
51 Two reviewers (TYT and YCS) independently screened titles and abstracts of all articles  
52  
53 identified by the search strategy. Inter-reviewer disagreements concerning the inclusion or  
54  
55 exclusion of a study were resolved by consensus and, if necessary, consultation with a third  
56  
57  
58  
59

reviewer (SHW).

The Cochrane Collaboration's tool was used to assess the risk of selection, performance, detection, attrition, and reporting biases in the included randomized trials.<sup>21</sup> We defined studies as "high risk of bias" if one or more key domains is taken as high risk in the checklist. All co-authors discussed and made the final decisions about the overall risk of bias in the included trials. If data were not readily available or clear, we contacted first authors and corresponding authors to get further information. If studies were found to be at high risk of bias, meta-analyses stratified by study quality were performed.

Both reviewers independently extracted data from the articles selected for inclusion. The extracted data included the name of the first author, year of publication, numbers of participants, gender, starting and final altitudes, AMS scoring definitions, prescriptions of GBE, days of treatment prior to ascent, and number of individuals with AMS in the treatment and control groups.

### **Patient and Public Involvement**

patients and or public were not involved directly in the systemic reviews.

### **Data collection, data processing, and primary data analysis**

Pooled relative risk (RR) with corresponding 95% confidence intervals (CIs) for each outcome of interest were calculated. The main outcome measure was the RR of AMS in participants receiving GBE for prophylaxis. Random effect models with DerSimonian and Laird method were selected for these analyses.

We conducted subgroup analyses based on quality of studies, starting altitude, number of treatment days before ascending, and dosage of GBE.<sup>22-24</sup> Between-study heterogeneity was evaluated with the  $I^2$  statistic.<sup>25</sup> The Egger regression asymmetry test and Begg adjusted rank correlation test were applied for assessment of potential publication bias.<sup>26 27</sup> We also

1  
2  
3 conducted sensitivity analysis to evaluate the influence of each study on the overall pooled  
4  
5 estimate. Analyses were all conducted using STATA version 11.0 (StataCorp, College Station,  
6  
7 Texas, USA). All statistical tests were two-sided and were considered significant when the P  
8  
9 value was 0.05 or less.  
10

## 11 12 13 14 **Results**

15 The literature search and study selection process are summarized in Figure 1. After the  
16  
17 exclusion of duplicate studies, non-relevant studies, and other studies that met exclusion  
18  
19 criteria based on a screening of article titles and abstracts, 38 potentially relevant studies  
20  
21 were retrieved for full review.  
22  
23

24 One publication was retrieved by hand search of the references. In this study, Wang et  
25  
26 al.<sup>28</sup> compared the prophylactic effect of GBE with that of other Chinese medications on  
27  
28 AMS. However, the study had no placebo group design<sup>29</sup> and had to be excluded from our  
29  
30 meta-analysis.  
31  
32

33 In the randomized double-blind study by Ke in 2013,<sup>20</sup> AMS was reported as a  
34  
35 secondary outcome and the number of events in each group were not reported. We  
36  
37 contacted the first and corresponding authors by email but (as of October 9, 2017) received  
38  
39 no response. Since the published data could not be included for analysis, we excluded this  
40  
41 study.  
42  
43  
44

45 Six published articles met all eligibility criteria after a careful review process.<sup>13 15-19</sup> In  
46  
47 the article published by Leadbetter et al.,<sup>19</sup> two randomized controlled trials were  
48  
49 conducted. As a result, a total of 7 study groups with 451 participants were enrolled. The  
50  
51 characteristics of these studies and the participants are listed in Table 1. Four study groups<sup>13</sup>  
52  
53  
54  
55  
56  
57  
58  
59  
60  
15 16 19 demonstrated the efficacy of GBE in preventing AMS, while three<sup>17-19</sup> did not. All

1  
2  
3 studies had small numbers of subjects except the one by Gertsch and colleagues.<sup>17</sup> Of note,  
4  
5 participants in the study conducted by Gertsch et al. published in 2004, started GBE  
6  
7 treatment at high altitude (4280–4358 m), which was different from the other studies.  
8  
9  
10 Further information such as study dosage, prescription frequency, number of days prior to  
11  
12 ascending, and source of GBE are summarized in Table 2. The number of AMS events and its  
13  
14 incidence are summarized in Figure 2. The evidence quality of these studies as assessed by  
15  
16 Cochrane Collaboration's tool is presented in Table 3. Two of 6 articles were not double-  
17  
18 blinded and both of them included male participants only.<sup>13 15</sup> The study conducted by  
19  
20 Gertsch et al. in 2002, used "first-come first-served basis" after receiving signed consent.  
21  
22 Therefore, we judge it as "unclear random-sequence generation".<sup>16</sup> In addition, we appraised  
23  
24 it as incomplete outcome data (attrition bias) because the study presented data on only 26  
25  
26 subjects when the intention was to enroll 100 subjects.  
27  
28

29  
30 In the primary meta-analysis of all 7 study groups, GBE showed trend of AMS prophylaxis,  
31  
32 but it is not statistically significant (RR =0.68; 95% CI: 0.45 to 1.04; p-value=0.08) (Figure 2).  
33  
34 The  $I^2$  statistic was 58.7% (p-value=0.02), indicating substantial heterogeneity. Pooled risk  
35  
36 difference is summarized in the additional supplementary figure 1. After excluding three  
37  
38 high-risk-bias studies,<sup>13 15 16</sup> the  $I^2$  statistic became 40.2% (p-value=0.17) and the result did  
39  
40 not change (RR =0.84; 95% CI 0.59 to 1.21; p-value=0.36). The Egger's-test and Begg-test (p-  
41  
42 values, 0.22 and 0.31, respectively) indicate the absence of statistical evidence of publication  
43  
44 bias after excluding our presumed high-risk-bias articles.  
45  
46  
47

48  
49 Sensitivity analysis was conducted by removing one trial at a time to determine what  
50  
51 influence each study had on the pooled analysis. The pooled result seemed to be robust. For  
52  
53 example, removing the study conducted by Leadbetter et al. in 2009<sup>19</sup> only changed the  
54  
55 pooled estimate from 0.79 to 0.74 (95% CI 0.48–1.16; p-value=0.19; see supplementary  
56  
57  
58  
59

figure 2).

The results of several pre-planned subgroup analyses were similar. Excluding the study by Gertsch and colleagues in 2004,<sup>17</sup> GBE was not prophylactic when the starting altitude was below 2500 m (RR =0.56; 95% CI 0.31 to 1.01)<sup>13 15 16 18 19</sup>. Regarding the number of treatment days before ascending, GBE was not prophylactic when given “3–5 days prior to ascent”<sup>18 19</sup> (RR =0.72; 95% CI 0.41 to 1.26) or “0–2 days prior to ascent”<sup>13 15-17</sup> (RR =0.56; 95% CI 0.25 to 1.25). Dosage of GBE was also not prophylactic for AMS when given “less than 200mg per day”<sup>13 15 16</sup> (RR =0.16; 95% CI 0.01 to 2.57) or “more than 200mg per day”<sup>17-19</sup> (RR =0.84; 95% CI 0.59 to 1.21).

## Discussion

To our knowledge, this is the first meta-analysis of RCTs evaluating GBE as an AMS prophylactic. In pooled analyses, we found that although GBE may tend toward AMS prophylaxis, it had no statistically significant prophylactic effect (RR =0.68; 95% CI: 0.45 to 1.04; p-value=0.08). The results of several subgroup analyses were similar. GBE also failed to show benefits in preventing AMS in low-risk bias studies, studies in which the starting altitude was low, studies differing in the initial treatment regimen prior to ascent, and different dosage of GBE.

The effectiveness of GBE in AMS prophylaxis has been reported.<sup>13 15 16 19</sup> Zhang and colleagues in 2003 reported that GBE was the most effective of six Chinese medicines tested for AMS prophylaxis.<sup>29</sup> GBE has been used primarily for the treatment of dementias (e.g., Alzheimer’s disease), peripheral vascular diseases (e.g., intermittent claudication), and neurosensory problems (e.g., tinnitus).<sup>30</sup> Hypotheses have been proposed to explain the possible role that GBE plays in preventing AMS. Hypoxia is a common feature of AMS. Several studies have suggested that nitric oxide (NO) may play a pathogenic role in AMS by

1  
2  
3 mediating hypoxia-induced cerebral vasodilation in humans.<sup>11-13</sup> GBE was found to be an NO  
4 scavenger. NO scavenging can result in decreased intracellular NO level.<sup>14</sup> Furthermore, GBE  
5 may inhibit phosphodiesterase activity, thus enhancing relaxation of parietal smooth muscle  
6 cells and so lead to vasodilation of parietal vessels. Vasodilation in turn increases tissue  
7 perfusion and decreases local hypoxia.<sup>14</sup> Other potential mechanisms include increasing  
8 endogenous antioxidants,<sup>31</sup> reducing free-radical production,<sup>32</sup> and reducing lung leak  
9 during hypoxia.<sup>33</sup> GBE was also shown to prevent high altitude pulmonary edema in a rat  
10 model.<sup>34</sup>

21 On the other hand, several studies failed to demonstrate the benefit of GBE in AMS  
22 prophylaxis.<sup>17 18 20</sup> The duration of therapy before ascent, dosage of GBE, and differences in  
23 the altitude at which GBE is initiated may account for the conflicts between trial results. To  
24 test these hypotheses, we conducted subgroup analyses and obtained similar results to  
25 those obtained with the original pooled data. Another explanation for the differences in  
26 efficacy may be variation in the GBE composition. For instance, Leadbetter and colleagues in  
27 2009 compared GBE from two different sources and found they differed in composition as  
28 well as ability to reduce the incidence and severity of AMS following rapid ascent to high  
29 altitude.<sup>19</sup> The German Federal Institute for Drugs and Medicinal Devices Commission E  
30 recommends similar specifications for standardization of GBE. All included studies used GBE  
31 that met the German E commission standard, but most of studies use products from  
32 different companies. As an herbal supplement, more than 60% of GBE component is not  
33 mandated by law and composition may vary considerably between manufacturers. A lack of  
34 bioequivalence has been noted between brands of GBE.<sup>35 36</sup>

### 53 Limitations

54 Our systematic review has several limitations. First, to limit the influence of study biases

1  
2  
3 on pooled evaluation, we decided to only include RCTs. However, there were few RCTs in this  
4  
5 field. Moreover, only 4 of 6 RCTs were double-blinded. Second, because of the difficulty in  
6  
7 carrying out high altitude medicine studies, many studies involved only a small number of  
8  
9 cases. In our primary pooled analysis, a total of 451 participants were enrolled. Insufficient  
10  
11 power may be an issue in this meta-analysis. There are not enough data to show the  
12  
13 statistically significant effect of GBE for preventing AMS, and further studies are warranted.  
14  
15 Third, the participants were predominantly adult males and whether there is gender or age  
16  
17 difference between treatment (GBE vs placebo) groups or response (no AMS vs AMS) groups  
18  
19 is unknown. Fourth, GBE is a complex mixture of natural components. It is difficult to  
20  
21 standardize all components. A lack of consistency between commercially available GBE  
22  
23 preparations may explain these differing results. Finally, differences between studies in  
24  
25 factors such as the strength, rate of ascent, and other characteristics of participants may also  
26  
27 account for inconsistent results.  
28  
29  
30  
31

### 32 **Conclusion**

33  
34  
35 The currently available data suggest that although GBE may tend toward AMS prophylaxis,  
36  
37 there are not enough data to show the statistically significant effect of GBE for preventing  
38  
39 AMS. Further large randomized control studies are warranted.  
40  
41  
42  
43

### 44 **Table and Figure Legends**

45  
46 Figure 1. Trial selection algorithm

47  
48 Figure 2. Events of acute mountain sickness between placebo and GBE, and forest plot of  
49  
50 meta-analysis.

51  
52 Table 1. Characteristics of included studies

53  
54 Table 2. Characteristics of included studies, sources, dosage and duration of GBE  
55  
56  
57  
58  
59  
60

1  
2  
3 Table 3. Risk of bias in included studies.  
4

5 **Declarations**

6  
7 **Consent for publication**

8  
9 Not applicable  
10

11  
12 **Competing interests**

13  
14 The authors declare that they have no competing interests in this section.  
15

16  
17 **Exclusive licence**

18  
19 The Corresponding Author has the right to grant on behalf of all authors and does grant on  
20  
21 behalf of all authors, a worldwide licence  
22  
23 ([http://www.bmj.com/sites/default/files/BMJ%20Author%20Licence%20March%202013.do](http://www.bmj.com/sites/default/files/BMJ%20Author%20Licence%20March%202013.doc)  
24  
25 c) to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether  
26  
27 known now or created in the future), to i) publish, reproduce, distribute, display and store  
28  
29 the Contribution, ii) translate the Contribution into other languages, create adaptations,  
30  
31 reprints, include within collections and create summaries, extracts and/or, abstracts of the  
32  
33 Contribution and convert or allow conversion into any format including without limitation  
34  
35 audio, iii) create any other derivative work(s) based in whole or part on the on the  
36  
37 Contribution, iv) to exploit all subsidiary rights to exploit all subsidiary rights that currently  
38  
39 exist or as may exist in the future in the Contribution, v) the inclusion of electronic links from  
40  
41 the Contribution to third party material where-ever it may be located; and, vi) licence any  
42  
43 third party to do any or all of the above. All research articles will be made available on an  
44  
45 Open Access basis (with authors being asked to pay an open access fee—see  
46  
47 [http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-](http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse)  
48  
49 [checklists/copyright-open-access-and-permission-reuse](http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse)). The terms of such Open Access  
50  
51 shall be governed by a Creative Commons licence—details as to which Creative Commons  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 licence will apply to the research article are set out in our worldwide licence referred to  
4  
5 above.

### 6 7 **Author contributions**

8  
9 TYT analyzed and interpreted the data and was a major contributor in writing the  
10  
11 manuscript. SHW interpreted the data. YKL supervised the study and interpreted the data.  
12  
13  
14 YCS analyzed the data and contribute in the manuscript formation. All authors read and  
15  
16 approved the final manuscript.  
17

### 18 19 **Transparency declaration**

20  
21 We affirm that the manuscript is an honest, accurate, and transparent account of the study  
22  
23 being reported; that no important aspects of the study have been omitted; and that any  
24  
25 discrepancies from the study as planned (and, if relevant, registered) have been explained.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Honigman B, Theis MK, Koziol-McLain J, et al. Acute mountain sickness in a general tourist population at moderate altitudes. *Annals of internal medicine* 1993;118(8):587-92. [published Online First: 1993/04/15]
2. Roach RC BP, Hackett PH, Oelz O. The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Coates G, Huston CS, eds. *Hypoxia and molecular medicine: proceedings of the 8th international hypoxia symposium* 1993; Lake Louise, Alberta, Canada. Burlington, VT: Queen City Printer:272-4.
3. Sampson JB, Cymerman A, Burse RL, et al. Procedures for the measurement of acute mountain sickness. *Aviation, space, and environmental medicine* 1983;54(12 Pt 1):1063-73. [published Online First: 1983/12/01]
4. Basnyat B, Murdoch DR. High-altitude illness. *Lancet (London, England)* 2003;361(9373):1967-74. doi: 10.1016/s0140-6736(03)13591-x [published Online First: 2003/06/13]
5. Shih-Hao Wang Y-CC, Wei-Fong Kao, Yu-Jr Lin, Jih-Chang Chen, Te-Fa Chiu, Tai-Yi Hsu, Hang-Cheng Chen, Shih-Wei Liu. Epidemiology of Acute Mountain Sickness on Jade Mountain, Taiwan: An Annual Prospective Observational Study. *High Altitude Medicine & Biology* 2010;11(1):43-49.
6. Chan CW, Lin YC, Chiu YH, et al. Incidence and risk factors associated with acute mountain sickness in children trekking on Jade Mountain, Taiwan. *Journal of travel medicine* 2016;23(1) doi: 10.1093/jtm/tav008 [published Online First: 2016/01/20]
7. Hackett PH, Yarnell PR, Hill R, et al. High-altitude cerebral edema evaluated with magnetic resonance imaging: clinical correlation and pathophysiology. *Jama* 1998;280(22):1920-5. [published Online First: 1998/12/16]
8. Schoene RB. Illnesses at high altitude. *Chest* 2008;134(2):402-16. doi: 10.1378/chest.07-0561
9. Zafren K. Prevention of high altitude illness. *Travel Medicine and Infectious Disease* 2014;12(1):29-39. doi: 10.1016/j.tmaid.2013.12.002
10. Seupaul RA, Welch JL, Malka ST, et al. Pharmacologic prophylaxis for acute mountain sickness: a systematic shortcut review. *Ann Emerg Med* 2012;59(4):307-17.e1. doi: 10.1016/j.annemergmed.2011.10.015 [published Online First: 2011/12/14]
11. Roach RC, Hackett PH. Frontiers of hypoxia research: acute mountain sickness. *The Journal of experimental biology* 2001;204(Pt 18):3161-70. [published Online First: 2001/10/03]
12. Van Mil AH, Spilt A, Van Buchem MA, et al. Nitric oxide mediates hypoxia-induced cerebral vasodilation in humans. *Journal of applied physiology (Bethesda, Md : 1985)* 2002;92(3):962-6. doi: 10.1152/jappphysiol.00616.2001 [published Online First: 2002/02/14]
13. Moraga FA, Flores A, Serra J, et al. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in Northern Chile. *Wilderness and Environmental Medicine* 2007;18(4):251-57. doi: 10.1580/06-WEME-OR-062R2.1
14. Marcocci L, Maguire JJ, Droy-Lefaix MT, et al. The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761. *Biochemical and biophysical research communications* 1994;201(2):748-55. [published Online First: 1994/06/15]
15. Roncin JP, Schwartz F, D'Arbigny P. EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. *Aviation, space, and environmental medicine* 1996;67(5):445-52. [published Online First: 1996/05/01]

16. Gertsch JH, Seto TB, Mor J, et al. Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. *High altitude medicine & biology* 2002;3(1):29-37. doi: 10.1089/152702902753639522 [published Online First: 2002/05/15]
17. Gertsch JH, Basnyat B, Johnson EW, et al. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). *BMJ (Clinical research ed)* 2004;328(7443):797. doi: 10.1136/bmj.38043.501690.7C [published Online First: 2004/04/09]
18. Chow T, Browne V, Heilesen HL, et al. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. *Archives of internal medicine* 2005;165(3):296-301. doi: 10.1001/archinte.165.3.296 [published Online First: 2005/02/16]
19. Leadbetter G, Keyes LE, Maakestad KM, et al. Ginkgo biloba does--and does not--prevent acute mountain sickness. *Wilderness & environmental medicine* 2009;20(1):66-71. doi: 10.1580/08-weme-br-247.1 [published Online First: 2009/04/15]
20. Ke T, Wang J, Swenson ER, et al. Effect of acetazolamide and ginkgo biloba on the human pulmonary vascular response to an acute altitude ascent. *High altitude medicine & biology* 2013;14(2):162-7. doi: 10.1089/ham.2012.1099 [published Online First: 2013/06/26]
21. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ (Clinical research ed)* 2011;343:d5928. doi: 10.1136/bmj.d5928 [published Online First: 2011/10/20]
22. Hackett PH, Roach RC. High-Altitude Illness. *New England Journal of Medicine* 2001;345(2):107-14. doi: 10.1056/nejm200107123450206
23. van Patot MC, Keyes LE, Leadbetter G, 3rd, et al. Ginkgo biloba for prevention of acute mountain sickness: does it work? *High altitude medicine & biology* 2009;10(1):33-43. doi: 10.1089/ham.2008.1085 [published Online First: 2009/03/13]
24. Dumont L, Mardirosoff C, Tramer MR. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. *BMJ (Clinical research ed)* 2000;321(7256):267-72. [published Online First: 2000/07/29]
25. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ (Clinical research ed)* 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557 [published Online First: 2003/09/06]
26. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50(4):1088-101. [published Online First: 1994/12/01]
27. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical research ed)* 1997;315(7109):629-34. [published Online First: 1997/10/06]
28. Wang J, Xiong X, Xing Y, et al. Chinese herbal medicine for acute mountain sickness: A systematic review of randomized controlled trials. *Evidence-based Complementary and Alternative Medicine* 2013;2013 doi: 10.1155/2013/732562
29. X. Z. Zhang HJY, Z. D. Ha et al. Role of six different medicines in the symptomatic scores of benign form of acute mountain sickness. *Medical Journal of National Defending Forces in Northwest China* 2003;24(5):341-43.
30. Sierpina VS, Wollschlaeger B, Blumenthal M. Ginkgo biloba. *Am Fam Physician*

- 1  
2  
3 2003;68(5):923-6. [published Online First: 2003/09/19]
- 4 31. Louajri A, Harraga S, Godot V, et al. The effect of ginkgo biloba extract on free radical  
5 production in hypoxic rats. *Biological & pharmaceutical bulletin* 2001;24(6):710-2.  
6 [published Online First: 2001/06/20]
- 7 32. Naik SR, Pilgaonkar VW, Panda VS. Evaluation of antioxidant activity of Ginkgo biloba  
8 phytosomes in rat brain. *Phytotherapy research : PTR* 2006;20(11):1013-6. doi:  
9 10.1002/ptr.1976 [published Online First: 2006/08/16]
- 10 33. Liu K-X, Wu W-K, He W, et al. Ginkgo biloba extract (EGb 761) attenuates lung injury  
11 induced by intestinal ischemia/reperfusion in rats: Roles of oxidative stress and nitric  
12 oxide. *World Journal of Gastroenterology : WJG* 2007;13(2):299-305. doi:  
13 10.3748/wjg.v13.i2.299
- 14 34. Berg JT. Ginkgo biloba extract prevents high altitude pulmonary edema in rats. *High*  
15 *altitude medicine & biology* 2004;5(4):429-34. doi: 10.1089/ham.2004.5.429  
16 [published Online First: 2005/01/27]
- 17 35. De Smet PA. Herbal remedies. *The New England journal of medicine* 2002;347(25):2046-  
18 56. doi: 10.1056/NEJMra020398 [published Online First: 2002/12/20]
- 19 36. Kressmann S, Muller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba  
20 brands. *The Journal of pharmacy and pharmacology* 2002;54(5):661-9. [published  
21 Online First: 2002/05/15]
- 22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Characteristics of included studies.

	Participants (number)	Male (%)	Starting altitude (m)	Altitude reached (m)	Ascent rate(m/h)	AMS definition
Roncin, 1996	44	100	1,800	5,400	15	AMS-C >0.7
Gertsch, 2002	26	46	0	4,205	1402	LLS ≥3 with HA
Gertsch, 2004	243	70	4,280–4,358	4,928	10-20	LLS ≥3 with HA
Chow, 2005	37	54	1,230	3,800	1285	LLS ≥3 with HA
Moraga, 2007	24	100	0	3,696	435	LLS ≥3, or 1 symptom score ≥3
Leadbetter, 2009 Study 1	40	45	2,000	4,300	1150	AMS-C ≥0.7 + LLS ≥3 with HA
Leadbetter, 2009 Study 2	37	44	2,000	4,300	1150	AMS-C ≥0.7 + LLS ≥3 with HA

GBE: ginkgo biloba extract; AMS: Acute mountain sickness; AMS-C: the Environmental Symptom Questionnaire III acute mountain sickness-cerebral (AMS-C) score; HA: headache; LLS: Lake Louise Score.

**Table 2.** Characteristics of included studies, sources, dosage and duration of ginkgo biloba.

	GBE source	Dose	Days of treatment prior to ascent
Roncin, 1996	Tanakan® DCI: EGb 761 Ipsen, Paris, France	60 mg BID	0
Gertsch, 2002	GK501 Memfit®, EGb 761, Pharmaton	60 mg TID	1
Gertsch, 2004	GK501 International, Pharmaton	120 mg BID	1–2
Chow, 2005	<i>Ginkgo biloba</i> 120 mg Vegetarian NOW® Foods	120 mg BID	5
Moraga, 2007	EGb 761 Rokan, Andromeco Laboratories, Chile	80 mg BID	1
Leadbetter, 2009 Study 1	Spectrum Quality, Laboratories Products, Inc.	120 mg BID	4
Leadbetter, 2009 Study 2	Technical Sourcing, Inc.	120 mg BID	3

BID: Bi in die=twice a day; TID: ter in die=three times a day.

**Table 3.** Risk of bias in included studies.

Risk of bias domain	Roncin, 1996	Gertsch, 2002	Gertsch, 2004	Chow, 2005	Moraga, 2007	Leadbetter, 2009
Random-sequence generation (selection bias)	Unclear	Unclear	Low	Low	Low	Low
Allocation concealment (selection bias)	Unclear	Low	Low	Low	Unclear	Low
Blinding of participants (performance bias)	High	Low	Low	Low	High	Low
Blinding of outcome assessment (detection bias)	High	Low	Low	Low	High	Low
Incomplete outcome data (attrition bias)	High	High	Low	Low	Low	Low
Selective outcome reporting (reporting bias)	Low	Low	Low	Low	Low	Low
Other source of bias	High	Low	High	Low	High	Low
<b>Overall risk of bias</b>	<b>High</b>	<b>High</b>	<b>Low</b>	<b>Low</b>	<b>High</b>	<b>Low</b>




Figure 1

190x142mm (300 x 300 DPI)







Figure 2. Events of acute mountain sickness between placebo and GBE, and forest plot of meta-analysis.

295x109mm (300 x 300 DPI)

Peer review only


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



88x61mm (300 x 300 DPI)

Review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



161x96mm (300 x 300 DPI)

Review only

Appendix Table. Secondary outcomes of included studies

		Incidence of severe AMS	Headache	Severe headache	Oxygen saturation	Pulmonary edema	Adverse events
Roncin, 1996	GBE	X	22/22 (100%)	0/22 (0%)	X	AMS-R >0.6 3/21 (13.6%)	GBE(18.2%) is less urine than Placebo(77.3%)
	Placebo	X	22/22 (100%)	0/22 (0%)	X	AMS-R >0.6 18/22 (81.8%)	
Gertsch, 2002	GBE	2/12 (16.7%)	X	1/12 (8%)	81%	X	No side effect in GBE
	Placebo	9/14 (64.3%)	X	1/14 (7%)	80%	X	
Gertsch, 2004	GBE	23/124 (18%)	72/124 (58%)	24/124 (19%)	79.5%	Non occurred	No side effect in GBE
	Placebo	22/119 (18%)	63/119 (53%)	16/119 (13%)	82.1% P<0.01		
Chow, 2005	GBE	X	GBE is 5% less than placebo		X	Non occurred	No side effect in GBE
	Placebo	X			X		
Moraga, 2007	GBE	X	LLS score, headache item 0.19±0.41		92±2%	X	X
	Placebo	X	1.28±0.14 P<0.05		84±3% P<0.01	X	X
Leadbetter, 2009(Study 1)	GBE	0/21 (0%)	X	X	X	X	X
	Placebo	3/19 (16%)	X	X	X	X	X
Leadbetter, 2009(Study 2)	GBE	3/15 (20%)	X	X	X	X	X
	Placebo	4/22 (18%)	X	X	X	X	X

AMS: Acute mountain sickness ; AMS-R: the Environmental Symptom Questionnaire III acute mountain sickness-Respiratory (AMS-R) score; GBE: ginkgo biloba extract; LLS: Lake Louise Score; X: not mentioned in the study.



# PRISMA 2009 Checklist

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N.A.
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	6



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	5
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	8
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	9
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	9
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	11
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	N.A.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

# BMJ Open

## Ginkgo Biloba Extract for Prevention of Acute Mountain Sickness: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022005.R2
Article Type:	Research
Date Submitted by the Author:	14-Jun-2018
Complete List of Authors:	Tsai, Tou-Yuan ; Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, Emergency Department WANG, SHIH-HAO; Chang Gung Memorial Hospital at Chiayi, Department of Physical Medicine and Rehabilitation Lee, Yi-Kung; Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, Emergency Department Su, Yung-Cheng; Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, Emergency Department
<b>Primary Subject Heading</b>:	Sports and exercise medicine
Secondary Subject Heading:	Emergency medicine, Occupational and environmental medicine
Keywords:	Ginkgo Biloba Extract, Acute Mountain Sickness, meta-analysis

SCHOLARONE™  
Manuscripts

Only

1  
2  
3 **Ginkgo Biloba Extract for Prevention of Acute Mountain Sickness: A Systematic Review and**  
4  
5 **Meta-analysis of Randomized Controlled Trials**  
6

7 Tou-Yuan Tsai, MD<sup>1,2</sup>; Shih-Hao Wang, MD<sup>2-5</sup>; Yi-Kung Lee, MD, MPH<sup>1,2</sup>; and Yung-Cheng Su,  
8  
9 MD, MPH.<sup>1,2</sup>  
10

11 **Institutions:**  
12

13  
14 <sup>1</sup>School of Medicine, Tzu Chi University, Hualien, Taiwan  
15

16 <sup>2</sup>Emergency Department, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation,  
17  
18 Chiayi, Taiwan  
19

20  
21 <sup>3</sup>Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at  
22  
23 Chiayi, Chiayi, Taiwan.  
24

25  
26 <sup>4</sup>Department of Recreation and Leisure Industry Management, College of Management,  
27  
28 National Taiwan Sport University, Taoyuan, Taiwan.  
29

30 <sup>5</sup>Taiwan Wilderness Medical Association, New Taipei City, Taiwan.  
31  
32  
33  
34

35 **Reprints and correspondence:**  
36

37 Yung-Cheng Su, MD, MPH.  
38

39 Emergency Department  
40

41 Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation  
42

43  
44 No. 2, Minsheng Rd., Dalin Township  
45

46 Chiayi County 622, Taiwan (R.O.C.)  
47

48  
49 Tel: 886-5-2648000 ext 5838  
50

51 Fax: 886-5-2648499  
52

53 E-mail: [drs119@gmail.com](mailto:drs119@gmail.com)  
54

55 **Running title:** Ginkgo Biloba Extract for Acute Mountain Sickness  
56  
57  
58  
59  
60



**Word count:**

Abstract: 250 words

Full text: 2382 words

**Number of references: 36****Number of tables: 3****Number of figures: 3****Author Disclosures:**

Dr. Tou-Yuan Tsai reports no disclosures.

Dr. Shih-Hao Wang reports no disclosures.

Dr. Yi-Kung Lee reports no disclosures.

Dr. Yung-Cheng Su reports no disclosures.

**Email address:**

Dr. Tou-Yuan Tsai: 96311123@gms.tcu.edu.tw

Dr. Shih-Hao Wang: mountainwangsh@gmail.com

Dr. Yi-Kung Lee: lyg1968@seed.net.tw

Dr. Yung-Cheng Su: [drsu119@gmail.com](mailto:drsu119@gmail.com)

**Author contributions:**

TYT analyzed and interpreted the data and was a major contributor in writing the manuscript. SHW interpreted the data. YKL supervised the study and interpreted the data. YCS interpreted the data and wrote the manuscript. All authors read and approved the final manuscript.

**Funding**

The authors did not receive any funding for this study.

**Availability of data and materials**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Extra data can be accessed via the Dryad data repository at <http://datadryad.org/> with the doi: 10.5061/dryad.35h13bg.

**Keywords:** Ginkgo Biloba Extract (GBE), Acute Mountain Sickness (AMS)

For peer review only

**Abstract****Study objective:**

Trials of ginkgo biloba extract (GBE) for the prevention of acute mountain sickness (AMS) have been published since 1996. Because of their conflicting results, the efficacy of GBE remains unclear. We performed a systematic review and meta-analysis to assess whether GBE prevents acute mountain sickness.

**Methods:**

The Cochrane Library, EMBASE, Google Scholar, and PubMed databases were searched for articles published up to May 20, 2017. Only randomized controlled trials were included. AMS defined as acute mountain sickness–cerebral(AMS-C) score  $\geq 0.7$  or Lake Louise Score (LLS)  $\geq 3$  with headache. The main outcome measures were the relative risks of AMS in participants receiving GBE for prophylaxis. Meta-analyses were conducted using random-effects models. Sensitivity analyses, subgroup analyses and tests for publication bias were conducted.

**Results:**

Seven study groups in 6 published articles met all eligibility criteria, including the article published by Leadbetter et al. which two randomized controlled trials were conducted. Overall, 451 participants were enrolled. In the primary meta-analysis of all 7 study groups, GBE showed trend of AMS prophylaxis, but it is not statistically significant (RR =0.68; 95% CI: 0.45 to 1.04; p-value=0.08). The  $I^2$  statistic was 58.7% (p-value=0.02), indicating substantial heterogeneity. The pooled risk difference (RD) revealed a significant risk reduction in participants with GBE use. (RD= -25%; 95% CI, from a reduction of 45% to 6%; p-value=0.011) The results of subgroup analyses of studies with low risk of bias, low starting altitude (<2500 m), number of treatment days before ascending and dosage of GBE are not

1  
2  
3 statistically significant.  
4

### 5 **Conclusions:**

6  
7 The currently available data suggest that although GBE may tend toward AMS prophylaxis,  
8  
9 there are not enough data to show the statistically significant effect of GBE for preventing  
10  
11  
12 AMS. Further large randomized control studies are warranted.  
13

### 14 **Strengths and limitations of this study**

- 15  
16 • This meta-analysis is the first systematic review and meta-analysis evaluating Ginkgo  
17  
18 Biloba Extract (GBE) as an Acute Mountain Sickness (AMS) prophylactic.
- 19  
20 • This meta-analysis strengthened by a thorough quality assessment of each enrolled  
21  
22 study and comprehensive subgroup analyses.
- 23  
24 • There is notable heterogeneity and the small number of studies limits the analyses,  
25  
26 but heterogeneity decreased after excluding studies with high risk of bias.
- 27  
28 • Insufficient power may be an issue in this meta-analysis. Further large randomized  
29  
30 control studies are warranted.  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **Introduction**

#### 41 **Background**

42  
43  
44 Rapid ascent from low to high altitude (> 2500 m above the sea level) is often followed  
45  
46 by headache, fatigue, shortness of breath, sleeplessness, and anorexia, a symptom complex  
47  
48 called acute mountain sickness (AMS).<sup>1</sup> Lake Louise Score (LLS) Questionnaires<sup>2</sup> and  
49  
50 Environmental Symptom Questionnaire III<sup>3</sup> are two tools to diagnose and evaluate severity  
51  
52 of AMS. AMS is more likely to happen at altitudes higher than 2500 m,<sup>4</sup> and worldwide  
53  
54 studies reported incidences of AMS of 25–37% at 1900–3400 m.<sup>1,5</sup> Children are more prone  
55  
56  
57  
58  
59  
60

1  
2  
3 to develop AMS, with an incidence of 59%.<sup>6</sup>  
4

5 The pathophysiology of AMS is associated with cerebral edema, with the most  
6 compelling evidence coming from the brain MRI study of Hackett et al.,<sup>7</sup> which showed  
7 intense T2 signals in the white matter, particularly in the splenium and corpus callosum.  
8 Vasogenic leakage increases permeability of the endothelium, causing an elevation in  
9 intravascular pressures and inducing hypoxemia. In addition, hypoxic ventilatory response  
10 and activation of the renin-angiotensin–aldosterone system are also reported to be  
11 associated with AMS.<sup>8</sup> The most effective method to prevent AMS is gradual ascent. The  
12 most common pharmacologic agent used to prevent AMS is acetazolamide.<sup>9</sup> However,  
13 acetazolamide can cause paresthesia, dysgeusia, and sometimes nausea or drowsiness.<sup>10</sup> Its  
14 use is also contraindicated in patients with a history of anaphylaxis to sulfa antibiotics or  
15 acetazolamide.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Importance**

31  
32 Ginkgo biloba extract (GBE) is an option for those seeking a natural alternative  
33 treatment. GBE is found to decrease the tissue hypoxia, induces vasodilation, reduces free-  
34 radical production and lung leak, which may in turn prevent AMS.<sup>11-14</sup> Roncin et al. in 1996  
35 published the first studies to suggest that GBE can prevent AMS.<sup>15</sup> However, not all  
36 subsequent studies have shown benefit.<sup>13 16-20</sup> To date, there is no best evidence to support  
37 the effectiveness of GBE.  
38  
39  
40  
41  
42  
43  
44  
45

### 46 **Goals of This Investigation**

47  
48 Our study aim was to assess the effectiveness of GBE in prophylaxis of AMS by  
49 conducting a meta-analysis and systematic review of the relevant literature.  
50  
51  
52  
53  
54

### 55 **Methods**

### **Databases and search strategy**

We searched the Cochrane Library, EMBASE, Google Scholar, and PubMed databases for articles published up to May 20<sup>th</sup>, 2017. No limits were applied to our Boolean search strategy, which included keywords ('Ginkgo', 'Altitude Sickness', 'Mountain'), Medical Subject Headings (MeSH) ('Ginkgo biloba', 'Altitude Sickness'), and Emtree terms ('Ginkgo biloba', 'altitude disease'). The full search strategy for database is provided in the supplementary file. References from retrieved articles were also examined to identify other relevant articles.

Studies were included in the systematic review if they were (1) randomized controlled trials (RCTs) of healthy non-acclimatized adult between age 18 and 60 years; (2) compared GBE with placebo; (3) conducted in humans; and (4) studies diagnosing AMS with the Lake Louise Score or AMS-C. We excluded studies which subjects were pregnant, had symptoms consistent with AMS at baseline. Studies were also excluded if they were irrelevant to the study's aim, were animal studies, lacked a placebo group, or were published as review articles, case reports, editorials, or letters. The systematic review and the meta-analysis was conducted under the PRISMA guidelines (see online supplementary Checklist). The Institutional Review Board of Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan, approved the protocol.

### **Outcome measures**

AMS defined as AMS-C score  $\geq 0.7$  or an LLS  $\geq 3$  with headache. Primary outcome were the relative risks of AMS in participants receiving GBE for prophylaxis. We only extracted data when they were available in dichotomous form. Secondary outcomes of included studies were summarized in supplementary Table 1.

### **Data extraction and assessment of methodological quality**

1  
2  
3 Two reviewers (TYT and YCS) independently screened titles and abstracts of all articles  
4 identified by the search strategy. Inter-reviewer disagreements concerning the inclusion or  
5 exclusion of a study were resolved by consensus and, if necessary, consultation with a third  
6 reviewer (SHW).  
7  
8  
9  
10

11 The Cochrane Collaboration's tool was used to assess the risk of selection, performance,  
12 detection, attrition, and reporting biases in the included randomized trials.<sup>21</sup> We defined  
13 studies as "high risk of bias" if one or more key domains is taken as high risk in the checklist.  
14 All co-authors discussed and made the final decisions about the overall risk of bias in the  
15 included trials. If data were not readily available or clear, we contacted first authors and  
16 corresponding authors to get further information. If studies were found to be at high risk of  
17 bias, meta-analyses stratified by study quality were performed.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 Both reviewers independently extracted data from the articles selected for inclusion.  
29 The extracted data included the name of the first author, year of publication, numbers of  
30 participants, gender, starting and final altitudes, AMS scoring definitions, prescriptions of  
31 GBE, days of treatment prior to ascent, and number of individuals with AMS in the  
32 treatment and control groups.  
33  
34  
35  
36  
37  
38  
39

#### 40 **Data collection, data processing, and primary data analysis**

41 Pooled relative risks (RR) with corresponding 95% confidence intervals (CIs) are derived  
42 for all studies and different subgroups of interest. The main outcome measure was the RR of  
43 AMS in participants receiving GBE for prophylaxis. Random effect models with DerSimonian  
44 and Laird method were selected for these analyses. The pooled risk difference (RD) was also  
45 measured as the alternative outcome. The pooled RD is the difference between the  
46 observed risks (proportions of participants with AMS) in the two groups.  
47  
48  
49  
50  
51  
52  
53  
54

55 We conducted subgroup analyses based on quality of studies, starting altitude, number  
56  
57  
58  
59  
60

1  
2  
3 of treatment days before ascending, and dosage of GBE.<sup>22-24</sup> Between-study heterogeneity  
4  
5 was evaluated with the  $I^2$  statistic.<sup>25</sup> The Egger regression asymmetry test and Begg adjusted  
6  
7 rank correlation test were applied for assessment of potential publication bias.<sup>26,27</sup> We also  
8  
9 conducted sensitivity analysis to evaluate the influence of each study on the overall pooled  
10  
11 estimate. For the zero cells dealing we add 0.5 to all cells of the  $2 \times 2$  table for the study.  
12  
13  
14 Analyses were all conducted using STATA version 11.0 (StataCorp, College Station, Texas,  
15  
16 USA). All statistical tests were two-sided and were considered significant when the P value  
17  
18 was 0.05 or less.  
19  
20

### 21 **Patient and Public Involvement statement**

22  
23 Participants and the public sector were not directly involved in the design and conduct of  
24  
25 this study.  
26  
27  
28  
29

### 30 **Results**

31 The literature search and study selection process are summarized in Figure 1. After the  
32  
33 exclusion of duplicate studies, non-relevant studies, and other studies that met exclusion  
34  
35 criteria based on a screening of article titles and abstracts, 38 potentially relevant studies  
36  
37 were retrieved for full review.  
38  
39

40  
41 One publication was retrieved by hand search of the references. In this study, Wang et  
42  
43 al.<sup>28</sup> compared the prophylactic effect of GBE with that of other Chinese medications on  
44  
45 AMS. However, the study had no placebo group design<sup>29</sup> and had to be excluded from our  
46  
47 meta-analysis.  
48  
49

50 In the randomized double-blind study by Ke in 2013,<sup>20</sup> AMS was reported as a  
51  
52 secondary outcome and the number of events in each group were not reported. We  
53  
54 contacted the first and corresponding authors by email but (as of June 12, 2018) received no  
55  
56  
57  
58  
59



1  
2  
3 response. Since the published data could not be included for analysis, we excluded this  
4  
5 study.

6  
7 Six published articles met all eligibility criteria after a careful review process.<sup>13 15-19</sup> In  
8  
9 the article published by Leadbetter et al.,<sup>19</sup> two randomized controlled trials were  
10  
11 conducted. As a result, a total of 7 study groups with 451 participants were enrolled. The  
12  
13 characteristics of these studies and the participants are listed in Table 1. Four study groups<sup>13</sup>  
14  
15 <sup>15 16 19</sup> demonstrated the efficacy of GBE in preventing AMS, while three<sup>17-19</sup> did not. All  
16  
17 studies had small numbers of subjects except the one by Gertsch and colleagues.<sup>17</sup> Of note,  
18  
19 participants in the study conducted by Gertsch et al. published in 2004, started GBE  
20  
21 treatment at high altitude (4280–4358 m), which was different from the other studies.  
22  
23 Further information such as study dosage, prescription frequency, number of days prior to  
24  
25 ascending, and source of GBE are summarized in Table 2. The number of AMS events and its  
26  
27 incidence are summarized in Figure 2. The evidence quality of these studies as assessed by  
28  
29 Cochrane Collaboration's tool is presented in Table 3. Two of 6 articles were not double-  
30  
31 blinded and both of them included male participants only.<sup>13 15</sup> The study conducted by  
32  
33 Gertsch et al. in 2002, used "first-come first-served basis" after receiving signed consent.  
34  
35 Therefore, we judge it as "unclear random-sequence generation".<sup>16</sup> In addition, we appraised  
36  
37 it as incomplete outcome data (attrition bias) because the study presented data on only 26  
38  
39 subjects when the intention was to enroll 100 subjects.  
40  
41  
42  
43  
44  
45

46  
47 In the primary meta-analysis of all 7 study groups, GBE showed trend of AMS prophylaxis,  
48  
49 but it is not statistically significant (RR =0.68; 95% CI: 0.45 to 1.04; p-value=0.08) (Figure 2).  
50  
51 The  $I^2$  statistic was 58.7% (p-value=0.02), indicating substantial heterogeneity. The pooled RD  
52  
53 revealed a significant risk reduction in participants with GBE use. (RD= -25%; 95% CI, from a  
54  
55 reduction of -45% to -6%; p-value<0.001) (Figure 3). After excluding three high-risk-bias  
56  
57  
58  
59  
60

1  
2  
3 studies,<sup>13 15 16</sup> the  $I^2$  statistic became 40.2% (p-value=0.17) and the result did not change (RR  
4 =0.84; 95% CI 0.59 to 1.21; p-value=0.36). In the same subgroup the pooled RD are also not  
5 statistically significant. (RD= -9.7%; 95% CI, from a reduction of -27.4% to 7.9%; p-  
6 value=0.28). The Egger's-test and Begg-test (p-values, 0.22 and 0.31, respectively) indicate  
7 the absence of statistical evidence of publication bias after excluding our presumed high-  
8 risk-bias articles.  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Sensitivity analysis was conducted by removing one trial at a time to determine what influence each study had on the pooled analysis. The pooled result seemed to be robust. For example, removing the study conducted by Leadbetter et al. in 2009<sup>19</sup> only changed the pooled estimate from 0.68 to 0.74 (95% CI 0.48–1.16; p-value=0.19; see supplementary figure 1).

The results of several pre-planned subgroup analyses were similar. Excluding the study by Gertsch and colleagues in 2004,<sup>17</sup> GBE was not prophylactic when the starting altitude was below 2500 m (RR =0.56; 95% CI 0.31 to 1.01)<sup>13 15 16 18 19</sup>. Regarding the number of treatment days before ascending, GBE was not prophylactic when given “3–5 days prior to ascent”<sup>18 19</sup> (RR =0.72; 95% CI 0.41 to 1.26) or “0–2 days prior to ascent”<sup>13 15-17</sup> (RR =0.56; 95% CI 0.25 to 1.25). Dosage of GBE was also not prophylactic for AMS when given “less than 200mg per day”<sup>13 15 16</sup> (RR =0.16; 95% CI 0.01 to 2.57) or “more than 200mg per day”<sup>17-19</sup> (RR =0.84; 95% CI 0.59 to 1.21). Information regarding number of participants and enrolled studies in each subgroup are summarized in supplementary table 2.

## Discussion

To our knowledge, this is the first meta-analysis of RCTs evaluating GBE as an AMS prophylactic. In pooled analyses, we found that although GBE may tend toward AMS prophylaxis, it had no statistically significant prophylactic effect (RR =0.68; 95% CI: 0.45 to

1  
2  
3 1.04; p-value=0.08). The results of several subgroup analyses were similar. GBE also failed to  
4  
5 show benefits in preventing AMS in low-risk bias studies, studies in which the starting  
6  
7 altitude was low, studies differing in the initial treatment regimen prior to ascent, and  
8  
9 different dosage of GBE.  
10

11  
12 The effectiveness of GBE in AMS prophylaxis has been reported.<sup>13 15 16 19</sup> Zhang and  
13  
14 colleagues in 2003 reported that GBE was the most effective of six Chinese medicines tested  
15  
16 for AMS prophylaxis.<sup>29</sup> GBE has been used primarily for the treatment of dementias (e.g.,  
17  
18 Alzheimer's disease), peripheral vascular diseases (e.g., intermittent claudication), and  
19  
20 neurosensory problems (e.g., tinnitus).<sup>30</sup> Hypotheses have been proposed to explain the  
21  
22 possible role that GBE plays in preventing AMS. Hypoxia is a common feature of AMS.  
23  
24 Several studies have suggested that nitric oxide (NO) may play a pathogenic role in AMS by  
25  
26 mediating hypoxia-induced cerebral vasodilation in humans.<sup>11-13</sup> GBE was found to be an NO  
27  
28 scavenger. NO scavenging can result in decreased intracellular NO level.<sup>14</sup> Furthermore, GBE  
29  
30 may inhibit phosphodiesterase activity, thus enhancing relaxation of parietal smooth muscle  
31  
32 cells and so lead to vasodilation of parietal vessels. Vasodilation in turn increases tissue  
33  
34 perfusion and decreases local hypoxia.<sup>14</sup> Other potential mechanisms include increasing  
35  
36 endogenous antioxidants,<sup>31</sup> reducing free-radical production,<sup>32</sup> and reducing lung leak  
37  
38 during hypoxia.<sup>33</sup> GBE was also shown to prevent high altitude pulmonary edema in a rat  
39  
40 model.<sup>34</sup>  
41  
42  
43  
44  
45

46  
47 On the other hand, several studies failed to demonstrate the benefit of GBE in AMS  
48  
49 prophylaxis.<sup>17 18 20</sup> The duration of therapy before ascent, dosage of GBE, and differences in  
50  
51 the altitude at which GBE is initiated may account for the conflicts between trial results. To  
52  
53 test these hypotheses, we conducted subgroup analyses and obtained similar results to  
54  
55 those obtained with the original pooled data. Another explanation for the differences in  
56  
57  
58  
59  
60

1  
2  
3 efficacy may be variation in the GBE composition. For instance, Leadbetter and colleagues in  
4  
5 2009 compared GBE from two different sources and found they differed in composition as  
6  
7 well as ability to reduce the incidence and severity of AMS following rapid ascent to high  
8  
9 altitude.<sup>19</sup> The German Federal Institute for Drugs and Medicinal Devices Commission E  
10  
11 recommends similar specifications for standardization of GBE. All included studies used GBE  
12  
13 that met the German E commission standard, but most of studies use products from  
14  
15 different companies. As an herbal supplement, more than 60% of GBE component is not  
16  
17 mandated by law and composition may vary considerably between manufacturers. A lack of  
18  
19 bioequivalence has been noted between brands of GBE.<sup>35 36</sup>  
20  
21  
22

### 23 **Limitations**

24  
25 Our systematic review has several limitations. First, to limit the influence of study biases  
26  
27 on pooled evaluation, we decided to only include RCTs. However, there were few RCTs in this  
28  
29 field. Moreover, only 4 of 6 RCTs were double-blinded. Second, because of the difficulty in  
30  
31 carrying out high altitude medicine studies, many studies involved only a small number of  
32  
33 cases. In our primary pooled analysis, a total of 451 participants were enrolled. Insufficient  
34  
35 power may be an issue in this meta-analysis. There are not enough data to show the  
36  
37 statistically significant effect of GBE for preventing AMS, and further studies are warranted.  
38  
39 Third, the participants were predominantly adult males and whether there is gender or age  
40  
41 difference between treatment (GBE vs placebo) groups or response (no AMS vs AMS) groups  
42  
43 is unknown. Fourth, GBE is a complex mixture of natural components. It is difficult to  
44  
45 standardize all components. A lack of consistency between commercially available GBE  
46  
47 preparations may explain these differing results. Finally, differences between studies in  
48  
49 factors such as the strength, rate of ascent, and other characteristics of participants may also  
50  
51 account for inconsistent results.  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Conclusion

The currently available data suggest that although GBE may tend toward AMS prophylaxis, there are not enough data to show the statistically significant effect of GBE for preventing AMS. Further large randomized control studies are warranted.

## Table and Figure Legends

Figure 1. Trial selection algorithm

Figure 2. Events of acute mountain sickness between placebo and GBE, and forest plot of meta-analysis.

Figure 3. Pooled risk difference of enrolled studies

Table 1. Characteristics of included studies

Table 2. Characteristics of included studies, sources, dosage and duration of GBE

Table 3. Risk of bias in included studies

## Declarations

### Consent for publication

Not applicable

### Competing interests

The authors declare that they have no competing interests in this section.

### Exclusive licence

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence (<http://www.bmj.com/sites/default/files/BMJ%20Author%20Licence%20March%202013.doc>) to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store

1  
2  
3 the Contribution, ii) translate the Contribution into other languages, create adaptations,  
4  
5 reprints, include within collections and create summaries, extracts and/or, abstracts of the  
6  
7 Contribution and convert or allow conversion into any format including without limitation  
8  
9 audio, iii) create any other derivative work(s) based in whole or part on the on the  
10  
11 Contribution, iv) to exploit all subsidiary rights to exploit all subsidiary rights that currently  
12  
13 exist or as may exist in the future in the Contribution, v) the inclusion of electronic links from  
14  
15 the Contribution to third party material where-ever it may be located; and, vi) licence any  
16  
17 third party to do any or all of the above. All research articles will be made available on an  
18  
19 Open Access basis (with authors being asked to pay an open access fee—see  
20  
21 <http://www.bmj.com/about-bmj/resources-authors/forms-policies-and->  
22  
23 [checklists/copyright-open-access-and-permission-reuse](http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse)). The terms of such Open Access  
24  
25 shall be governed by a Creative Commons licence—details as to which Creative Commons  
26  
27 licence will apply to the research article are set out in our worldwide licence referred to  
28  
29 above.  
30  
31  
32  
33

### 34 35 **Author contributions**

36  
37 TYT analyzed and interpreted the data and was a major contributor in writing the  
38  
39 manuscript. SHW interpreted the data. YKL supervised the study and interpreted the data.  
40  
41 YCS analyzed the data and contribute in the manuscript formation. All authors read and  
42  
43 approved the final manuscript.  
44  
45

### 46 47 **Transparency declaration**

48  
49 We affirm that the manuscript is an honest, accurate, and transparent account of the study  
50  
51 being reported; that no important aspects of the study have been omitted; and that any  
52  
53 discrepancies from the study as planned (and, if relevant, registered) have been explained.  
54  
55  
56  
57  
58  
59

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## References

1. Honigman B, Theis MK, Koziol-McLain J, et al. Acute mountain sickness in a general tourist population at moderate altitudes. *Annals of internal medicine* 1993;118(8):587-92. [published Online First: 1993/04/15]
2. Roach RC BP, Hackett PH, Oelz O. The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Coates G, Huston CS, eds. *Hypoxia and molecular medicine: proceedings of the 8th international hypoxia symposium* 1993; Lake Louise, Alberta, Canada. Burlington, VT: Queen City Printer:272-4.
3. Sampson JB, Cymerman A, Burse RL, et al. Procedures for the measurement of acute mountain sickness. *Aviation, space, and environmental medicine* 1983;54(12 Pt 1):1063-73. [published Online First: 1983/12/01]
4. Basnyat B, Murdoch DR. High-altitude illness. *Lancet (London, England)* 2003;361(9373):1967-74. doi: 10.1016/s0140-6736(03)13591-x [published Online First: 2003/06/13]
5. Shih-Hao Wang Y-CC, Wei-Fong Kao, Yu-Jr Lin, Jih-Chang Chen, Te-Fa Chiu, Tai-Yi Hsu, Hang-Cheng Chen, Shih-Wei Liu. Epidemiology of Acute Mountain Sickness on Jade Mountain, Taiwan: An Annual Prospective Observational Study. *High Altitude Medicine & Biology* 2010;11(1):43-49.
6. Chan CW, Lin YC, Chiu YH, et al. Incidence and risk factors associated with acute mountain sickness in children trekking on Jade Mountain, Taiwan. *Journal of travel medicine* 2016;23(1) doi: 10.1093/jtm/tav008 [published Online First: 2016/01/20]
7. Hackett PH, Yarnell PR, Hill R, et al. High-altitude cerebral edema evaluated with magnetic resonance imaging: clinical correlation and pathophysiology. *Jama* 1998;280(22):1920-5. [published Online First: 1998/12/16]
8. Schoene RB. Illnesses at high altitude. *Chest* 2008;134(2):402-16. doi: 10.1378/chest.07-0561
9. Zafren K. Prevention of high altitude illness. *Travel Medicine and Infectious Disease* 2014;12(1):29-39. doi: 10.1016/j.tmaid.2013.12.002
10. Seupaul RA, Welch JL, Malka ST, et al. Pharmacologic prophylaxis for acute mountain sickness: a systematic shortcut review. *Ann Emerg Med* 2012;59(4):307-17.e1. doi: 10.1016/j.annemergmed.2011.10.015 [published Online First: 2011/12/14]
11. Roach RC, Hackett PH. Frontiers of hypoxia research: acute mountain sickness. *The Journal of experimental biology* 2001;204(Pt 18):3161-70. [published Online First: 2001/10/03]
12. Van Mil AH, Spilt A, Van Buchem MA, et al. Nitric oxide mediates hypoxia-induced cerebral vasodilation in humans. *Journal of applied physiology (Bethesda, Md : 1985)* 2002;92(3):962-6. doi: 10.1152/jappphysiol.00616.2001 [published Online First: 2002/02/14]
13. Moraga FA, Flores A, Serra J, et al. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in Northern Chile. *Wilderness and Environmental Medicine* 2007;18(4):251-57. doi: 10.1580/06-WEME-OR-062R2.1
14. Marcocci L, Maguire JJ, Droy-Lefaix MT, et al. The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761. *Biochemical and biophysical research communications* 1994;201(2):748-55. [published Online First: 1994/06/15]
15. Roncin JP, Schwartz F, D'Arbigny P. EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. *Aviation, space, and environmental medicine* 1996;67(5):445-52. [published Online First: 1996/05/01]



16. Gertsch JH, Seto TB, Mor J, et al. Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. *High altitude medicine & biology* 2002;3(1):29-37. doi: 10.1089/152702902753639522 [published Online First: 2002/05/15]
17. Gertsch JH, Basnyat B, Johnson EW, et al. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). *BMJ (Clinical research ed)* 2004;328(7443):797. doi: 10.1136/bmj.38043.501690.7C [published Online First: 2004/04/09]
18. Chow T, Browne V, Heilesen HL, et al. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. *Archives of internal medicine* 2005;165(3):296-301. doi: 10.1001/archinte.165.3.296 [published Online First: 2005/02/16]
19. Leadbetter G, Keyes LE, Maakestad KM, et al. Ginkgo biloba does--and does not--prevent acute mountain sickness. *Wilderness & environmental medicine* 2009;20(1):66-71. doi: 10.1580/08-weme-br-247.1 [published Online First: 2009/04/15]
20. Ke T, Wang J, Swenson ER, et al. Effect of acetazolamide and ginkgo biloba on the human pulmonary vascular response to an acute altitude ascent. *High altitude medicine & biology* 2013;14(2):162-7. doi: 10.1089/ham.2012.1099 [published Online First: 2013/06/26]
21. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ (Clinical research ed)* 2011;343:d5928. doi: 10.1136/bmj.d5928 [published Online First: 2011/10/20]
22. Hackett PH, Roach RC. High-Altitude Illness. *New England Journal of Medicine* 2001;345(2):107-14. doi: 10.1056/nejm200107123450206
23. van Patot MC, Keyes LE, Leadbetter G, 3rd, et al. Ginkgo biloba for prevention of acute mountain sickness: does it work? *High altitude medicine & biology* 2009;10(1):33-43. doi: 10.1089/ham.2008.1085 [published Online First: 2009/03/13]
24. Dumont L, Mardirosoff C, Tramer MR. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. *BMJ (Clinical research ed)* 2000;321(7256):267-72. [published Online First: 2000/07/29]
25. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ (Clinical research ed)* 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557 [published Online First: 2003/09/06]
26. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50(4):1088-101. [published Online First: 1994/12/01]
27. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical research ed)* 1997;315(7109):629-34. [published Online First: 1997/10/06]
28. Wang J, Xiong X, Xing Y, et al. Chinese herbal medicine for acute mountain sickness: A systematic review of randomized controlled trials. *Evidence-based Complementary and Alternative Medicine* 2013;2013 doi: 10.1155/2013/732562
29. X. Z. Zhang HJY, Z. D. Ha et al. Role of six different medicines in the symptomatic scores of benign form of acute mountain sickness. *Medical Journal of National Defending Forces in Northwest China* 2003;24(5):341-43.
30. Sierpina VS, Wollschlaeger B, Blumenthal M. Ginkgo biloba. *Am Fam Physician*

- 1  
2  
3 2003;68(5):923-6. [published Online First: 2003/09/19]  
4 31. Louajri A, Harraga S, Godot V, et al. The effect of ginkgo biloba extract on free radical  
5 production in hypoxic rats. *Biological & pharmaceutical bulletin* 2001;24(6):710-2.  
6 [published Online First: 2001/06/20]  
7 32. Naik SR, Pilgaonkar VW, Panda VS. Evaluation of antioxidant activity of Ginkgo biloba  
8 phytosomes in rat brain. *Phytotherapy research : PTR* 2006;20(11):1013-6. doi:  
9 10.1002/ptr.1976 [published Online First: 2006/08/16]  
10 33. Liu K-X, Wu W-K, He W, et al. Ginkgo biloba extract (EGb 761) attenuates lung injury  
11 induced by intestinal ischemia/reperfusion in rats: Roles of oxidative stress and nitric  
12 oxide. *World Journal of Gastroenterology : WJG* 2007;13(2):299-305. doi:  
13 10.3748/wjg.v13.i2.299  
14 34. Berg JT. Ginkgo biloba extract prevents high altitude pulmonary edema in rats. *High*  
15 *altitude medicine & biology* 2004;5(4):429-34. doi: 10.1089/ham.2004.5.429  
16 [published Online First: 2005/01/27]  
17 35. De Smet PA. Herbal remedies. *The New England journal of medicine* 2002;347(25):2046-  
18 56. doi: 10.1056/NEJMra020398 [published Online First: 2002/12/20]  
19 36. Kressmann S, Muller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba  
20 brands. *The Journal of pharmacy and pharmacology* 2002;54(5):661-9. [published  
21 Online First: 2002/05/15]  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Characteristics of included studies.

	Participants (number)	Male (%)	Starting altitude (m)	Altitude reached (m)	Ascent rate(m/h)	AMS definition
Roncin, 1996	44	100	1,800	5,400	15	AMS-C >0.7
Gertsch, 2002	26	46	0	4,205	1402	LLS ≥3 with HA
Gertsch, 2004	243	70	4,280–4,358	4,928	10-20	LLS ≥3 with HA
Chow, 2005	37	54	1,230	3,800	1285	LLS ≥3 with HA
Moraga, 2007	24	100	0	3,696	435	LLS ≥3, or 1 symptom score ≥3
Leadbetter, 2009 Study 1	40	45	2,000	4,300	1150	AMS-C ≥0.7 + LLS ≥3 with HA
Leadbetter, 2009 Study 2	37	44	2,000	4,300	1150	AMS-C ≥0.7 + LLS ≥3 with HA

GBE: ginkgo biloba extract; AMS: Acute mountain sickness; AMS-C: the Environmental Symptom Questionnaire III acute mountain sickness-cerebral (AMS-C) score; HA: headache; LLS: Lake Louise Score.

**Table 2.** Characteristics of included studies, sources, dosage and duration of ginkgo biloba.

	GBE source	Dose	Days of treatment prior to ascent
Roncin, 1996	Tanakan® DCI: EGb 761 Ipsen, Paris, France	60 mg BID	0
Gertsch, 2002	GK501 Memfit®, EGb 761, Pharmaton	60 mg TID	1
Gertsch, 2004	GK501 International, Pharmaton	120 mg BID	1–2
Chow, 2005	<i>Ginkgo biloba</i> 120 mg Vegetarian NOW® Foods	120 mg BID	5
Moraga, 2007	EGb 761 Rokan, Andromeco Laboratories, Chile	80 mg BID	1
Leadbetter, 2009 Study 1	Spectrum Quality, Laboratories Products, Inc.	120 mg BID	4
Leadbetter, 2009 Study 2	Technical Sourcing, Inc.	120 mg BID	3

BID: Bi in die=twice a day; TID: ter in die=three times a day.

**Table 3.** Risk of bias in included studies.

Risk of bias domain	Roncin, 1996	Gertsch, 2002	Gertsch, 2004	Chow, 2005	Moraga, 2007	Leadbette r, 2009
Random-sequence generation (selection bias)	Unclear	Unclear	Low	Low	Low	Low
Allocation concealment (selection bias)	Unclear	Low	Low	Low	Unclear	Low
Blinding of participants (performance bias)	High	Low	Low	Low	High	Low
Blinding of outcome assessment (detection bias)	High	Low	Low	Low	High	Low
Incomplete outcome data (attrition bias)	High	High	Low	Low	Low	Low
Selective outcome reporting (reporting bias)	Low	Low	Low	Low	Low	Low
Other source of bias	High	Low	High	Low	High	Low
<b>Overall risk of bias</b>	<b>High</b>	<b>High</b>	<b>Low</b>	<b>Low</b>	<b>High</b>	<b>Low</b>




Figure 1

190x142mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2. Events of acute mountain sickness between placebo and GBE, and forest plot of meta-analysis.

419x297mm (300 x 300 DPI)





Figure 3. Pooled risk difference of enrolled studies

297x209mm (300 x 300 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



161x96mm (300 x 300 DPI)

Review only

1 The full search strategy for Pubmed is as followings:

2 We use the following search string: ("Ginkgo biloba"[Mesh] or "ginkgo"[tiab]) AND( "Altitude  
3 Sickness"[Mesh] or "Altitude Sickness"[tiab] or "mountain"[tiab])  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Supplementary Table 1. Secondary outcomes of included studies

		Incidence of severe AMS	Headache	Severe headache	Oxygen saturation	Pulmonary edema	Adverse events
Roncin, 1996	GBE	X	22/22 (100%)	0/22 (0%)	X	AMS-R >0.6 3/21 (13.6%)	GBE(18.2%) is less urine than Placebo(77.3%)
	Placebo	X	22/22 (100%)	0/22 (0%)	X	AMS-R >0.6 18/22 (81.8%)	
Gertsch, 2002	GBE	2/12 (16.7%)	X	1/12 (8%)	81%	X	No side effect in GBE
	Placebo	9/14 (64.3%)	X	1/14 (7%)	80%	X	
Gertsch, 2004	GBE	23/124 (18%)	72/124 (58%)	24/124 (19%)	79.5%	Non occurred	No side effect in GBE
	Placebo	22/119 (18%)	63/119 (53%)	16/119 (13%)	82.1% P<0.01		
Chow, 2005	GBE	X	GBE is 5% less than placebo		X	Non occurred	No side effect in GBE
	Placebo	X			X		
Moraga, 2007	GBE	X	LLS score, headache item 0.19±0.41		92±2%	X	X
	Placebo	X	1.28±0.14 P<0.05		84±3% P<0.01	X	X
Leadbetter, 2009(Study 1)	GBE	0/21 (0%)	X	X	X	X	X
	Placebo	3/19 (16%)	X	X	X	X	X
Leadbetter, 2009(Study 2)	GBE	3/15 (20%)	X	X	X	X	X
	Placebo	4/22 (18%)	X	X	X	X	X

AMS: Acute mountain sickness ; AMS-R: the Environmental Symptom Questionnaire III acute mountain sickness-Respiratory (AMS-R) score; GBE: ginkgo biloba extract; LLS: Lake Louise Score; X: not mentioned in the study.

Supplementary Table 2. Number of participants and enrolled studies in each subgroup

Subgroup	Number of participants
<i>Low risk of bias studies</i>	357
Gertsch, 2004	
Chow, 2005	
Leadbetter, 2009	
<i>Starting altitude below 2500m</i>	208
Roncin, 1996	
Gertsch, 2002	
Chow, 2005	
Moraga, 2007	
Leadbetter, 2009	
<i>3–5 days prior to ascent</i>	114
Chow, 2005	
Leadbetter, 2009	
<i>0–2 days prior to ascent</i>	337
Roncin, 1996	
Gertsch, 2002	
Gertsch, 2004	
Moraga, 2007	
<i>Dosage less than 200mg per day</i>	94
Roncin, 1996	
Gertsch, 2002	
Moraga, 2007	
<i>Dosage more than 200mg per day</i>	357
Gertsch, 2004	
Chow, 2005	
Leadbetter, 2009	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



# PRISMA 2009 Checklist

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N.A.
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	6



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	5
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	8
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	9
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	9
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	11
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	N.A.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).